Portuguese Biotechnology.
PortugueseBiotechnology.
biotechnology.
Portuguese
Lifeabove
aboveall.
all.
Life
PortugueseBiotechnology
Biotechnology Directory
Directory
Portuguese
Portuguese biotechnology.
Life above all.
Portuguese Biotechnology Directory
Life Sciences & Biotechnology
THE PORTUGUESE BIOTECHNOLOGY SECTOR PROFILE
The Portuguese Biotechnology sector has experienced, over the last few years, an important and significant increase in the number of companies
created.
Presently, there are over 40 Biotechnology start-ups companies in Portugal, most of which were created between 2001 and 2006.
In general, the companies have between 5 to 20 highly qualified human resources, distributed over the areas of Lisbon, Porto/Braga and Coimbra
/Aveiro.
The area of activity more frequent is Healthcare&Medical, followed by Agro-Food and Environmental Biotechnology.
Although the Biotechnology sector in Portugal is still emerging, its potential of growth and development is very high. There are highly qualified
human resources, internationally recognized, essential for the success of this industry, in addition to an increasing interest towards the new
(bio)technologies, particularly among the investor community as well as in the new governmental programs of support for scientific and
technological areas. This arousing interest is very important for the success and for a consistent and competitive development of the sector.
Most Portuguese Biotechnology start-up companies have a strong internationalization focus, which is an important feature that guaranties the
competitive advantages of the companies in this technological based sector.
Evolution Of The Portuguese Biotechnology Landscape
1996
1998
2000
There are companies which have more than one area of activity. In the previous graphic, each company is represented with the color that corresponds to
its primary area of activity. Foreign and multinational companies located in Portugal, as well as Portuguese Pharmaceutical companies were not
considered in this directory.
2002
2004
2006
This third edition of the Portuguese Biotechnology Directory pretends to illustrate a reliable picture of the Biotechnology sector in Portugal,
providing a list of companies and R&D centers with facts and figures for a more comprehensive source of information. We hope this report will
enhance the knowledge for Portuguese Biotechnology and thus promote its further development.
We would like to acknowledge Margarida Fontes PhD for all the support and valid contribution to the assembly of the Portuguese Biotehnology
Directory 2006.
Lisbon
On behalf of the editors of the Portuguese _Biotechnology Directory,
APBio, the Portuguese Bioindustries Association
Oporto
Braga
Coimbra
Aveiro
Other
Each bubble represents a biotech company
The size of the bubble represents
10 employees
the number of employees:
Made byAPBio based on the Portuguese Biotech Directory 2006
The areas of activity are represented by different colours:
Healthcare & Medical
Bioprocess Technology
Marine
Food
Agro--Food
Environment
Technology Transfer
DIRECTORY
5
GY
LO
GY
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
TE
SS
BI
PR
,I
ER
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
7
NT
CU
IN
X
X
N
O
BA
TI
ST
IN
D
R&
X
X
CE
ES
IT
UT
GY
LO
NO
CH
TE
S
SF
AN
TR
CS
AT
I
RM
FO
IN
O
BI
X
X
3B’S
AIBILI
BIOCANT
CBQF
CEB
CEBQ
CIDEB
CMDT
CNC
CQFB
IBET
IBMC
ICAT
IGC
IICT
IMM
INEB
INETI
INIAP
INOVAR & CRESCER
INSA
IPATIMUP
ITQB
REQUIMTE
TECMINHO
DIRECTORY
ER
O
TA
TI
EN
RM
FE
L
CA
SI
AS
CL
X
X
6
S
O
BI
N,
ES
RI
ST
DU
IN
O
BI
ED
AS
-B
NE
GE
PR
GY
NO
CH
OT
E
BI
TA
L
EN
NM
RO
VI
EN
LO
GY
LO
NO
CH
OT
E
BI
L
RA
O
CE
E
IN
AR
M
D
AN
TA
L
UL
TU
IC
X
X
X
X
X
X
CH
CH
OT
E
E
NC
IE
SC
N
O
TI
UT
RE
LT
U
AG
R
AQ
X
X
X
X
X
AS
,C
O
LO
NO
OT
E
BI
D
O
UA
CU
CH
AL
M
ED
IC
X
X
FO
HE
AL
TH
,
Y]
IT
IV
[A
CT
IN
NECTON
PROENOL
SIMBIENTE
STAB VIDA
TECHNOPHAGE
THERAPROTEINS
VSBV
WEDO TECH
GY
,N
OS
,D
IA
GN
S
ER
BA
TI
CU
ST
IN
D
N
O
IT
UT
CE
ES
NT
AN
TR
R&
RI
CS
TI
S
PR
,I
ER
SF
X
X
X
X
GY
LO
NO
CH
TE
X
NO
LO
NO
TE
CE
O
O
BI
CS
AT
I
RM
FO
O
BI
CL
AS
IN
SI
-B
CA
AS
L
ED
FE
BI
O
RM
IN
EN
DU
TA
TI
ST
O
RI
N,
ES
NO
CH
OT
E
BI
TA
L
EN
NE
GE
PR
GY
LO
GY
LO
NO
CH
NM
RO
VI
EN
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
OT
E
BI
L
RA
UL
TU
IC
AG
R
X
X
X
SS
BI
E
IN
AR
M
D
TA
L
AN
UT
AS
,C
O
RE
LT
U
X
X
X
X
X
X
X
X
CH
CH
OT
E
E
NC
IE
SC
N
O
TI
RI
CS
TI
LO
NO
CH
AQ
UA
CU
D
O
FO
HE
GY
,N
,D
IA
GN
OS
AL
BI
OT
E
M
ED
IC
AL
TH
,
Y]
IT
IV
[A
CT
[COMPANIES]
ALFAMA
ATGC
BEBE VIDA
BIOALVO
BIOCODEX
BIOEPI
BIOESTRATEGIA
BIOGNOSIS
BIOPREMIER
BIOSTRUMENT
BIOSURFIT
BIOTECA
BIOTECNOL
BIOTEMPO
BIOTESTE
BIOTREND
BLUEPHARMA
CPC
CRIOESTAMINAL
CYTOTHERA
EC-BIO
EUROTRIALS
FOODMETRIC
GENE EXPRESS
GENE PREDIT
GENEBOX
GENELAB
GENETEST
GENIBET
GENOMED
HALORIS
IMUNOSTAR
INTRANSTEC
ITB
Portuguese Biotechnology.
Life above all.
[COMPANIES]
8
Portuguese Biotechnology
DIRECTORY
9
Portuguese Biotechnology.
Life above all.
[1]
[1]
ALFAMA
ATGC
Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda
Gabinete Comercialização Ciência Lda
> ADDRESS: Taguspark, Núcleo Central 267 > ZIP CODE: 2740-122 > CITY: OEIRAS
> ADDRESS: Av da República. Estação Agronómica Nacional, ITQBII. Sto António de Oeiras > ZIP CODE: 2781-601 > CITY: OEIRAS
> PHONE: +351 214 240 001 > FAX: +351 214 240 033 > EMAIL: [email protected] > WEB SITE: www.alfama.com.pt
> PHONE: +351 214 469 760 > FAX: +351 214 469 740 > EMAIL: [email protected] > WEB SITE: www. atgcportugal.com
> PERSON TO BE CONTACTED: Agnes Lopes
> PERSON TO BE CONTACTED: Daniela Leão
[2]
Area of Biotech Activities
Health, Medical, Diagnostics
[3]
Activity > Alfama develops proprietary drugs for the treatment
of inflammation-related diseases.
Type of activity > Products and/or technologies from own R&D
Start up (year) > 2002
Structure of the capital > Private Limited Company
Percentage owned by founders > 68%
Total funds raised > 4,5 Million EUR
Total number of employees: 13
PhD: 9 > Master of Science: 1 > Graduate: 2
Percentage of employees involved in R&D Activities: 70%
R&D Expenses (% turnover 2005) > 70%
Number of International patents:
Submitted: 13 > Awarded: 3
[5]
Company Profile
“ALFAMA is a young pharmaceutical company dedicated to
the development of small-molecule drugs for the combat
against inflammation-related diseases. The company’s proprietary
technologies hold the promise of contributing decisively to the
prevention and cure of inflammatory diseases such as rheumatoid
arthritis, asthma, psoriasis and IBD, as well as inflammation-related
problems such as stroke, myocardial infarction, atherosclerosis and
Alzheimer’s disease.
The core of ALFAMA’s science is developed in Portugal, where
the company was started, at state-of-the-art research facilities
around the Lisbon area. The company’s financial organization, on
the other hand, complies with American standards and is based in
Cambridge, MA (USA), where the holding company, ALFAMA Inc,
is located.”
[4]
Products > anti-inflammatory pharmaceutical drugs
Core technologies > Alfama’s core technology is based on the
delivery of carbon monoxide (CO) to target tissues through the use
of CO-releasing molecules (CORMs).
Target markets > Pharmaceutical
Facilities > Lisbon, Oeiras, Porto Salvo (Portugal); Cambridge MA
(USA)
Technological relationships >Harvard Medical School (USA),
University of Catania (Italy), INETI (Portugal),
Universidade de Aveiro (Portugal), IMM (Portugal), ITQB/IBET
(Portugal), Frimorfo (Switzerland)
Other relevant partnerships > Wilmer, Cutler, Pickering,
Hale and Dorr, Boston MA (USA); Gonçalves Pereira, Castelo Branco
& Associados (Portugal)
10
[2]
Area of Biotech Activities
Health, Medical, Diagnostics > Technology Transfer, IPRs
[3]
Activity > Technology transfer, licensing and spin-off generation in
the biomedical field
Type of activity > Services
Start up (year) > 2002
Structure of the capital > Private limited company
Percentage owned by founders > 100%
Total funds raised > 2.000 EUR
Total number of employees: 3
PhD: 1 > Master of Science: 1 > Graduate: 1
academic labs, and take them to the industry through licensing
agreements or the creation of spin-out companies.
ATGC builds solid relationships with academic labs, particularly in
Southern Europe, and helps scientists transform their work into
life-saving products developed by biotech and pharma companies
worldwide.
ATGC manages a portfolio of cutting-edge technologies in fields
such as cancer diagnostics, skin and nerve repair, the synthesis of
acetic acid, and anti-inflammatory drugs. In this latter field ATGC
has recently helped launch a first, very promising spin-off named
Alfama.”
[4]
Services > Technology transfer and licensing in the biomedical
field. Technologies commercialised: New method for the synthesis
of Acetic acid; Screening kit for Intestinal Metaplasia; Treated
amniotic membranes for regeneration of skin, peripheral nerve
and retina.
Target markets > Pharmaceutical, biotechnology and medical
device industries.
Facilities > IBET in Oeiras, Portugal
Main clients > Pharmaceutical and chemical companies
Technological relationships > Instituto Superior Técnico (IST,
Lisbon), Instituto de Tecnologia Química e Biológica (ITQB, Oeiras),
Stab Vida Lda. (Oeiras), Alfama Lda. (Oeiras), Instituto Gulbenkian
de Ciência (IGC, Oeiras), Instituto de Patologia
e Imunologia Molecular da Universidade do Porto (IPATIMUP,
Porto), Taguspark (Oeiras).
[5]
Company Profile
“ATGC is engaged in the commercialisation of scientific
breakthroughs. The company finds technologies generated within
Portuguese Biotechnology
DIRECTORY
11
Portuguese Biotechnology.
Life above all.
[1]
[1]
BEBE VIDA
BIOALVO
Provision of Health Care Services, Ltd / European Biomedical Institute
Serviços, Investigação e Desenvolvimento em Biotecnologia, S.A.
> ADDRESS: Parque Tecnológico da Mutela, Av. Aliança Povo, MFA > ZIP CODE: 2804-537 > CITY: ALMADA
> ADDRESS: Edifício ICAT - Campus da FCUL; Campo Grande > ZIP CODE: 1749-016 > CITY: Lisboa
> PHONE: +351 212 744 021/2 > FAX: +351 212 744 023 > EMAIL: [email protected] > WEB SITE: www.bebevida.com
> PHONE: +351 217 500 217 > FAX: +351 217 500 220
> PERSON TO BE CONTACTED: Silvia Martins / Nuno Araújo
> PERSON TO BE CONTACTED: Helena Vieira
Technological relationships > European Biomedical Institute
- Portugal
Other relevant partnerships > Labmed - Heatlh Care
[2]
Area of Biotech Activities
Health, Medical, Diagnostics
[3]
Activity > We provide both comercial and laboratorial services on
the cryopreservation of cord blood stem cells and on adult stem
cells. We also have the skills to determine the child’s sex from the
eight week of pregnancy.
Type of activity > Products and/or technologies from own R&D >
Services
Start up (year) > Bebé Vida - 2004; European Biomedical Institute
- 2006
Structure of the capital > Joint Stock Company
Percentage owned by founders > 100%
Total funds raised > 2 Million Euro
Total number of employees: 6
Master of Science: 1 > Graduate: 4
R&D Expenses (% turnover 2005) > 5%
[5]
Company Profile
“Developing services relating to the cryopreservation of stem cells,
Bebevida is currently the leader in Portugal. This company was
acquired by the European Biomedical Institute in 2006, and the
cryopreservation of stem cells is carried out at the European
Biomedical Institute. Bebevida is currently preparing for international
expansion, providing all levels of support for investors interested in
partnership with the company.”
[3]
Activity > Biopharmaceutical
Type of activity > Products and/or technologies from own R&D
> Services
Start up (year) > 2005
Structure of the capital > Public limited company
Percentage owned by founders > 52% promoters, 48% PME
Investimentos
Total funds raised > 1,3 Million EUR
Total number of employees: 6
PhD: 2 > Master of Science: 2 > Graduate: 2
Percentage of employees involved in R&D Activities: 100%
Number of International patents:
To be submitted until the end of 2006
[5]
Company Profile
“BIOALVO is specialized in the research lead drug discovery process
and in the early preclinical phase of the drug development
process. Our main strategy is to develop projects from the
exploratory research phase until the end of the preclinical stage.
The company may advantageously perform further drug
development depending on a cautious risk/profit analysis.
BIOALVO operates an alliance based research and develop
business model. The company designs strategies that effectively
lead to the development of early-stage drugs and disease
treatments using molecular approaches to drug discovery.
The promising candidates obtained with BIOALVO’s drug
development programmes allow the company to build up
significantly its portfolio. The company relies on collaborative
research agreements to fill its pipeline and to bring its products to
the market. Research licensing agreements between global
pharmaceutical companies and BIOALVO provide the necessary
financial and complementary resources for late stages clinical
development and marketing.”
[4]
Products > TTR Silencer; Blockade
Services > TTR Silencer; Blockade; cell culture services; candidate
drug screening
Core technologies > Mammalian cell culture and yeast screening
platforms; silencing RNA system
Target markets > Neurological biotech and pharmaceutical
companies
Facilities > Biosafety Level 2+ lab with microscopy facilities;
Molecular and Celular biology and biochemistry lab; office
Main clients > Pharma and biotech companies; academia
Technological relationships > ICAT (Portugal); FCUL (Portugal);
IGC (Portugal); FEUCP (Portugal); Imperial College (UK)
[4]
Services > Stem Cell Cryopreservation Services
Target markets > For the cord blood stem cells our main target are
pregant women and a large number of people in risk groups, such
as: - smokers; - those with a family clinical history of heart disease;
- people with a high level of radiation exposure at work, such as
flight crews. The cryopreservation of adult stem cells is available
for all groups. We provide a great opportunity for healthy people
to cryopreserve their stem cells. The number of diseases that are
curable with stem cells is growing every day at an impressive rate.
For the service to find out a child’s gender during the eighth week
of pregancy, our targets are all women expecting children. There’s
a great expectation from parents to know their babies sex as soon
as possible, and our lab gives them that chance.
Facilities > Laboratory and Front Office
Main clients > Parents to be
12
[2]
Area of Biotech Activities
Health, Medical, Diagnostics > Gene-based Bioindustries
> Bioinformatics
Portuguese Biotechnology
DIRECTORY
13
Portuguese Biotechnology.
[1]
Life above all.
[1]
BIOCODEX
BIOEPI
Incubação de Empresas de Ciências da Vida, S.A.
Clinical and Translational Research Center, Lda
> ADDRESS: Rua do Campo Alegre, 823 > ZIP CODE: 4150-180 > CITY: PORTO
> ADDRESS: Taguspark, Nucleo Central, 244 > ZIP CODE: 2740-122 > CITY: OEIRAS
> PHONE: +351 226 074 949 > FAX: +351 22 6 099 157 > EMAIL: [email protected] > WEB SITE: www.biocodex.pt
> PHONE: +351 214 211 726 > EMAIL: [email protected] > WEB SITE: www.bioepi.com
> PERSON TO BE CONTACTED: Mariana Americano
> PERSON TO BE CONTACTED: Vasco Benito-Garcia
[2]
Area of Biotech Activities
Health, Medical, Diagnostics
[2]
Area of Biotech Activities
Health, Medical, Diagnostics
[3]
Activity > Incubation and business development
Type of activity > Services
Start up (year) > 2002
Structure of the capital > Public limited company
Percentage owned by founders > 45% Grupo Lena,
45% PME Capital, 10% António Parada
Turnover (2005): 129.952 EUR
Total number of employees: 5
PhD: 5
Percentage of employees involved in R&D Activities: 40%
[3]
Activity > Clinical Research, Epidemiology and Translational
Research
Type of activity > Contract research > Services
Start up (year) > 2006
Structure of the capital > Private limited company
Percentage owned by founders > Partners and Management
Total number of employees: 10
PhD: 1 > Master of Science: 2 > Graduate: 3
Percentage of employees involved in R&D Activities: 90%
[4]
Services > Clinical Trials, Epidemiology Studies, Biostatistics, Cost
effectiveness Analysis, Pharmacovigilance, Post-Marketing Surveillance
Target markets > Biotechnology Industry,
Pharmaceutical companies, Public Health decision makers. etc.
Facilities > Office at Taguspark
Pilot facilities > Access to pilot facilities through partnerships with
CROs and industries
Main clients > Arthritis Foundation (USA), Schering Plough
Other relevant partnerships > NDB-National DataBank for
Rheumatic Diseases, Wichita, Kansas, USA; Nurses Health Study,
Harvard Medical School, Harvard University, Boston, MA, USA.;
Service de Rheumatologie, Hopitaux Universitaires de Genéve,
Genéve, Suisse; Robert B. Brigham Arthritis and Musculoskeletal
Research Center, Division of Rheumatology, Immunology, and
Allergy, Brigham and Women’s Hospital, Boston, MA, USA;
Departamento de Higiene e Epidemiologia da Faculdade de
Medicina do Porto, Hospital de São João do Porto, Portugal;
Instituto Ricardo Jorge, Lisboa, Portugal.
[4]
Services > Incubation and consulting to start-up Life Sciences
companies
Target markets > Start-up Life Sciences
companies
Facilities > Spain
Pilot facilities > Portugal
Main clients >Bioteca, Genetest, Imunostar
Technological relationships > IBMC
Other relevant partnerships > Bebé Vida Espanha
[5]
Company Profile
“The Biocodex is the answer to the necessities of universities,
institutes and researchers that put on the market their technology
from life sciences.”
14
Portuguese Biotechnology
DIRECTORY
[5]
Company Profile
“Created in 2006, BioEPI, Clinical & Translational Research Center is a
multidisciplinary patient-oriented research and epidemiology center,
working towards prevention and control of chronic diseases while
trying to serve with quality and efficiency, those who seek our
services.
Bioepi offers the following services to the scientific community:
Study Design and Protocol Development, Biometrics, Training
Programs, Design and Monitoring of Clinical Trials, Post-Marketing
Surveillance, Database Development and Data Management, and
many other services that will help clients to better understand the
needs in their research and challenges in their clinical activities.
BioEPI mission is to improve the health condition of patients
suffering from chronic diseases worldwide, by leading
comprehensive clinical and translational research programs
and epidemiologic studies, providing health science and our
customers with a deeper understanding of today’s clinical
challenges. Bioepi’s aim is to deliver research-based results that will
enhance the quality, efficacy and cost-effectiveness of our
customers’ products and services. The excellence and
experience of the people, the rigor of their methods, their
customer-focused result-oriented attitude and their ethical values
are a guarantee of successful results and long-lasting
relationships”.
15
Portuguese Biotechnology.
[1]
Life above all.
[1]
BIOESTRATÉGIA
BIOGNOSIS
Consultoria, Formação, Management, Tecnologia e Inovação, Lda
Comércio de Produtos Biológicos para Diagnóstico Lda
> ADDRESS: Rua de Olivença, nº 3-A r/c > ZIP CODE: 8700-413 > CITY: OLHÃO
> ADDRESS: Rua 1º Dezembro,243-2º-sala 2.1 > ZIP CODE: 4450-227 > CITY: MATOSINHOS
> PHONE: +351 289 715 946 > FAX: +351 289 715 028 > EMAIL: [email protected]
> PHONE: +351 229 352 404 > EMAIL: [email protected] > WEB SITE: [email protected]
> PERSON TO BE CONTACTED: Florbela Soares / Teresa Baptista
> PERSON TO BE CONTACTED: Maria do Céu Amaral / João teixeira
[2]
Area of Biotech Activities
Aquaculture, Coastal and Marine Biotech > Environmental
Biotechnology
[3]
Activity > R&D, consultancy and training in aquaculture and
fisheries
Start up (year) > 1995
Structure of the capital > Private limited company
Percentage owned by founders > 50% Teresa Baptista; 50%
Florbela Soares
Total number of employees: 5
PhD: 1 > Master of Science: 1 > Graduate: 1
Percentage of employees involved in R&D Activities: 50%
R&D Expenses (% turnover 2005) > 50%
The company works in technology applied to bivalve depuration,
hygiene rules and procedures in larval production and trophic
chain of marine fish larvae. Also provides consultancy in the area of
pathological analysis of marine fish and monitoring of production
conditiona in fishfarms. Training programs are offered in several
areas, namely fish production and quality. “
[2]
Area of Biotech Activities
Health, Medical, Diagnostics
[3]
Type of activity > Products and/or technologies from own R&D
Start up (year) > 2005
Structure of the capital > Private limited company
Percentage owned by founders > 100%
Number of International patents:
Submitted: 01
[4]
Products > Easy-copros (concentration of intestinal parasites)
other products for medical or veterinary diagnostics
Facilities > Biocant
Technological relationships > INSA
[4]
Products > Diagnostic and Therapeutics
Services > R&D services in the field of Aquaculture Development.
Services are also provided in tree other areas: Consultancy in
aquaculture; Training in Aquaculture and fisheries related areas;
Pathological analyses in the fisheries area.
Target markets > Aquaculture and bivalve depuration centers
Main clients > Aquaculture and bivalve depuration centers
Technological relationships >University of Algarve - Portugal;
IPIMAR - Portugal e DGPA - Portugal
[5]
Company Profile
“Biognosis is a biotechnology –based private company, which
congregates commum strategic interests from investigators and
private investors in the news challenges of a modern economy.
The main target of Biognosis is the development, the production
and trade of new laboratory tools for human and veterinary
diagnosis. Parasite infestations are prominent in our R&D activity.
Biognosis is looking into useful, simple and relevant solutions for
laboratory activity.”
[5]
Company Profile
“Bioestratégia was founded in 16 of October 1995. Its main
purposes are: conducting Research and Scientific Development
on Aquaculture and Fisheries areas and providing Consultancy,
Technical Assistance and Management, Vocational Training in the
Aquaculture and Fisheries, Trade, Industry and Tourism, Alternative
Energy Environmental and Natural Resources areas.
16
Portuguese Biotechnology
DIRECTORY
17
Portuguese Biotechnology.
[1]
Life above all.
[1]
BIOPREMIER
BIOSTRUMENT
Inovação e Serviços em Biotecnologia, SA
Consultadoria e Desenvolvimento de Projectos Bioquímicos, Lda
> ADDRESS: Ed. ICAT. Campus da Fac. de Ciências da Univ. de Lisboa. Campo Grande > ZIP CODE: 1749-016 > CITY: Lisboa
> ADDRESS: Rua Dr. António Bernardino de Almeida > ZIP CODE: 4200-072 > CITY: PORTO
> PHONE: +351 217 500 218 > FAX: +351 217 500 172 > EMAIL: [email protected] > WEB SITE: www.biopremier.com
> PHONE: +351 225 020 172 > FAX: +351 225 097 255 > EMAIL: [email protected] > WEB SITE: www.biostrument.com
> PERSON TO BE CONTACTED: Manuel Rodrigues
> PERSON TO BE CONTACTED: Rui Meireles de Barros
[2]
Area of Biotech Activities
Health, Medical, Diagnostics > Food Biotechnology, Nutrition
Science
[3]
Type of activity > Products and/or technologies from own R&D >
Services > Contract research
Start up (year) > 2003
Structure of the capital > Public limited company
Total funds raised > 500.000 EUR
Total number of employees: 5
PhD: 1 > Graduate: 4
Percentage of employees involved in R&D Activities: 60%
agri-food sector, which will enable the detection and identification
of mixture of species in processed food (meat and fish species).
Furthermore, the company is studying new methods and designing
molecules for detection of pathogenic and food-spoilage microorganisms. Complementary, the services provided by the company are
applied to Taxonomy, Genetic Diversity and Epidemiology, through the
study of the nucleic acids. Using technology based on molecular
biology and bioinformatics tools Biopremier performs identification
of species, evaluation of microbiotic diversity, populational studies
applied to microbiology and research by contract.”
[4]
Products > Development of kits for the diagnosis of infectious
diseases and food-spoilage microorganisms.
Services > Identification of species, Species authentication,
Microbiotic diversity, Epidemiology, Data Analysis, Research by
Contract
Target markets > Clinical and Agri-food sector
Facilities > Biopremier is located at the Institute for Applied
Science and Technology
Pilot facilities > The company uses labs at the Institute for Applied
Science and Technology
Technological relationships > Institute for Applied Science and
Technology, New University of Lisbon
process, practices, and/or procedures problems, but also to issues
relating to scientific activities.”
[3]
Type of activity > Products and/or technologies from own R&D
> Services > Commercialisation/distribution of third party
products
Start up (year) > 2002
Structure of the capital > Private limited company
Percentage owned by founders > 100%
Total funds raised > 800.000 EUR
Total number of employees: 10
PhD: 3 > Graduate: 7
Percentage of employees involved in R&D Activities: 20%
R&D Expenses (% turnover 2005) > 25%
[4]
Products > Qualfood, Labset, Softset
Services > HACCP implementation
Target markets > Food Industry, Laboratory Analysis
Main clients > Controlvet, Sagilab, Carina, Sonae
[5]
Company Profile
“Biostrument is devoted to develop synergies between scientific
knowledge and industries. Our focus is to provide innovative
solutions to problems arising in industries and labs, in order to
increase and optimize their technological indexes. Biostrument
offers scientific, engineering and technical consulting services in
order to improve Industrial Technology Process, mainly on
agro-food industries. Biostrument also provides consulting
services on development and control of analytical methods,
software development, and on implementation of Food Safety
programs (HACCP). Biostrument could give an innovative service
and cost-effective on alternative solutions, not only to engineering
[5]
Company Profile
“Biopremier performs research and development of new
diagnostic products and provides services based on molecular
biology. Regarding R&D activities, Biopremier is proceeding to the
final development of kits for species authentication in
18
[2]
Area of Biotech Activities
Food Biotechnology, Nutrition Science > Technology Transfer, IPRs
Portuguese Biotechnology
DIRECTORY
19
Portuguese Biotechnology.
Life above all.
[1]
[1]
BIOSURFIT
BIOTECA
Biosurfit, SA
Bioteca, SA
> ADDRESS: Centro Empresarial de Aveiro > ZIP CODE: 3811-501 > CITY: AVEIRO
> ADDRESS: Rua Castilho, 59 - 6.º Esq. > ZIP CODE: 1250-068 > CITY: LISBOA
> PHONE: +351 217 500 213 > FAX: +351 217 500 172 > EMAIL: [email protected] > WEB SITE: www.biosurfit.com
> PHONE: +351 213 812 819 > FAX: +351 213 873 989 > EMAIL: [email protected] > WEB SITE: www.bioteca.eu
> PERSON TO BE CONTACTED: João Garcia da Fonseca
> PERSON TO BE CONTACTED: Paulo Teodora
[2]
Area of Biotech Activities
Health, Medical, Diagnostics
[2]
Area of Biotech Activities
Health, Medical, Diagnostics
[3]
Type of activity > Products and/or technologies from own R&D
Start up (year) > 2006
Structure of the capital > Public limited company
Percentage owned by founders > Venture Capital + Investment of
Founders
Total funds raised > 1,3 Million EUR
Total number of employees: 6
PhD: 2 > Graduate: 4
Percentage of employees involved in R&D Activities: 100%
Number of national patents:
Submitted: 02
[3]
Activity > Cryopreservation, research and development in stem
cells
Type of activity > Services
Start up (year) > 2005
Structure of the capital > Public limited company
Total number of employees: 5
PhD: 3 > Graduate: 2
Percentage of employees involved in R&D Activities: 60%
[4]
Services > Cryopreservation of stem cells
Target markets > Health services
[4]
Products > New platform for point of care tesing
Core technologies > Opto-electronic enhanced detection coupled
with improved microfluidic mechanisms
Target markets > Medical diagnostics, point of care
Technological relationships > Biosurfit is a spinoff from
Universidade de Lisboa
[5]
Company Profile
“Bioteca is the first cryopreservation laboratory in Portugal.”
[5]
Company Profile
“Biosurfit currently develops a new point of care detection
platform based on a new enhanced surface plasmon resonance
technique, with sufficent sensibility of medical diagnostics at low
cost.”
20
Portuguese Biotechnology
DIRECTORY
21
Portuguese Biotechnology.
[1]
Life above all.
[1]
BIOTECNOL
BIOTEMPO
Biotecnol, SA
Biotechnology Consulting, Ltd.
> ADDRESS: Lagoas Park, Edifício 7, Piso 1 Norte > ZIP CODE: 2741-901 > CITY: PORTO SALVO
> ADDRESS: Praça Camilo Castelo Branco, nº 6 > ZIP CODE: 4700-209 > CITY: BRAGA
> PHONE: +351 214 220 520 > FAX: +351 214 220 529 > EMAIL: [email protected] > WEB SITE: www.biotecnol.com
> PHONE: +351 253 265 696 > FAX: +351 253 265 665 > EMAIL: [email protected] > WEB SITE: www.biotempo.com
> PERSON TO BE CONTACTED: Luis Amado
> PERSON TO BE CONTACTED: Isabel Rocha
[2]
Area of Biotech Activities
Health, Medical, Diagnostics> Gene-based Bioindustries
> Technology Transfer, IPRs > Bioinformatics
[3]
Type of activity > Products and/or technologies from own R&D
(50%) > Contract research (30%) > Services (20%)
Start up (year) > 1996 as a consultancy company; re-structured in
2000 as a product development company
Structure of the capital > Public limited company
Percentage owned by founders > 50%
Turnover (2005): 0,6 Million EUR
Foreign revenue (%turnover 2005): 100%
Total number of employees: 17
PhD: 5 > Master of Science: 2 > Graduate: 10
Percentage of employees involved in R&D Activities: 75%
R&D Expenses (% turnover 2005) > 60%
Number of International patents: 70
Submitted: 25 > Awarded: 45
[4]
Products > GM031 (GM-CSF); IL-13; IR051- anti-HER2 Immunotoxin;
IR052- anti-HER2 dimeric Immunotoxin; CAB051 - novel anti-HER2
antibody; anti-CD155 antibody; anti-HSP90 antibody; Cardiothrophin 1
Services > Process & product development; analytical
development.
Core technologies > The Tribody™ technology allows to produce
multivalent/multispecific antibody derivatives. A Tribody™ consists
of fusions of scFv (or any other type of binder) molecules to the
C-termini of both antibody Fab chains.
The Fastscreen® Technology is a precious aid in clone selection
for development of biopharmaceuticals. Fastscreen® is a highthroughput technology for selecting expression strategies in
several hosts.
22
Target markets > Oncology, Immunology, Process development,
Product development
Facilities > 800 sq metres of sate of the art biological
development facilities where activities are divided in the following
areas: Molecular Biology; Cell & Tissue Culture; Analytics;
Fermentation; Downstream Processing
Pilot facilities > Fermentation; Unit with various reactors ranging
from 3 to 7 L dedicated to developmet activities. 100 L pilot facility
expected to be operational in 2007
Technological relationships > IDM, Inc; Flamel Technologies; VIB,
Belgium; University of Naples; Tufts University
[5]
Company Profile
“Biotecnol is a biotechnology company focused on the
development of biopharmaceuticals. Biotecnol has a special focus
on the development of antibody-based therapeutics to treat
life-threatening diseases. Biotecnol applies its Tribody™
technology, product development and manufacturing experience
to generate, support and potentially license human antibody
products. Biotecnol is committed in building value by developing
a diverse pipeline of antibody products to address unmet
healthcare needs. Biotecnol also leverages its business income by
establishing in-house partner-led or collaborative programmes.
Biotecnol uses its proprietary expression technology, cell line
development capabilities, upstream and downstream processing,
analytics and QC experience for delivering GMP/GLP compliant
processes for biomanufacturing. Biotecnol has several internal
development programmes in oncology and a strong client-based
activity.”
Portuguese Biotechnology
[2]
Area of Biotech Activities
Bioinformatics > Classical Fermentation, Bioprocess Technology
> Environmental Biotechnology > Food Biotechnology, Nutrition
Science
[3]
Activity > BIOTEMPO promotes a strong cooperation between
academic research and industrial applications, aiming the
development of new products and innovative solutions,
contributing to the differentiation of its clients in food,
pharmaceutical and environmental biotechnology.
Type of activity > Products and/or technologies from own R&D
> Contract research > Services
Start up (year) > 2002
Structure of the capital > Private limited company
Percentage owned by founders > 100%
Turnover (2005): 50.000 EUR
Total number of employees: 8
PhD: 3 > Master of Science: 2 > Graduate: 2
Percentage of employees involved in R&D Activities: 75%
R&D Expenses (% turnover 2005) > 50%
Number of national patents:
Submitted: 01
[4]
Products > Functional food ingredientes - oligosaccharides with
prebiotic characteristics (under development - it is foreseen that
the products will be on the market in 2008); software for monitoring
and evaluating the performance of wastewater treatment plants
Services > Contract Research; Consultancy (in food safety and
technology and environmental biotechnology); Advanced courses
Core technologies > Fermentation technology for the production
of functional food ingredients, proteins and chemicals; software
and technologies for the evaluation of the performance of
wastewater treatment plants; enzymatic technology
DIRECTORY
Target markets > Food industry, wastewater treatment plants,
research institutes, biotech companies
Facilities > Biotech research laboratories; administrative offices;
professional training rooms
Pilot facilities > A 1 m3 capacity fermentation pilot plant is being
projected
Main clients > Food industries, Universities, wastewater treatment
plants, hospitals
Technological relationships > Biological Engineering
Department and Computer Science Research Center (University
of Minho – Portugal); Polytechnic Institute of Bragança (Portugal);
University of Porto
Other relevant partnerships > Biotempo participates in the
Network of Excellence (funded by the European Comission)
HARMONY - Harmonizing nutrient recommendations across Europe
with special focus on vulnerable groups and consumer understanding
[5]
Company Profile
“BIOTEMPO offers consulting and applied R&D services, and
promotes its own projects with the purpose of developing
high-valued products and innovative processing solutions.
These activities are developed within the two intervention units of
the company. The main services offered by the Food and Industrial
Biotechnology Unit are: implementation, auditing and certification
of food safety management systems; study of new processes,
equipments or products; design and optimisation of novel fermentation
processes. The main services of Environmental Biotechnology Unit
are: evaluation of biological processes by the diagnosis and technical
support of wastewater treatment plants - technical support in the
development of new wastewater treatment plants and on the
re-evaluation of existing ones. Some of Biotempo’s R&D projects
are related with the Development of New Functional Foods,
Optimisation of Recombinant Microorganisms Fermentation and
Development of New Tools for the Evaluation of Wastewater
Treatment Performance.”
23
Portuguese Biotechnology.
[1]
Life above all.
[1]
BIOTESTE
BIOTREND
Biotecnologicas de ADN, Lda
Inovação e Engenharia em Biotecnologia, SA
> ADDRESS: Rua Antonio Jose Batista, 86 > ZIP CODE: 2910-397 > CITY: SETUBAL
> ADDRESS: Rua Torcato Jorge, Nº41, c/v Dta > ZIP CODE: 2620-295 > CITY: RAMADA
> PHONE: +351 265 231 854 > FAX: +351 265 520 567 > EMAIL: [email protected] > WEB SITE: www.bioteste.pt
> PHONE: +351 218 419 189 > FAX: +351 218 419 189 > EMAIL: [email protected] > WEB SITE: www.biotrend.biz
> PERSON TO BE CONTACTED: Susana Figueiredo
> PERSON TO BE CONTACTED: Bruno Sommer Ferreira
[2]
Area of Biotech Activities
Health, Medical, Diagnostics> Food Biotechnology, Nutrition
Science > Environmental Biotechnology
[2]
Area of Biotech Activities
Classical Fermentation, Bioprocess Technology > Gene-based
Bioindustries > Food Biotechnology, Nutrition Science
[3]
Activity > Veterinarian molecular diagnosis and veterinarian
biological testing
Type of activity > Products and/or technologies from own R&D
Start up (year) > 2003
Structure of the capital > Private limited company
Total number of employees: 2
Graduate: 2
[3]
Activity > Industial biotechnology process development;
production of food and feed additives
Type of activity > Products and/or technologies from own R&D
> Contract research > Services
Start up (year) > 2000
Structure of the capital > Public limited company
Percentage owned by founders > Founders + VC Investment
Total funds raised > 425.000 EUR
Turnover (2005): 19.334 EUR
Total number of employees: 4
PhD: 2 > Graduate: 2
Percentage of employees involved in R&D Activities: 75%
R&D Expenses (% turnover 2005) > 100%
Number of national patents:
Submitted: 01
Number of International patents:
Submitted: 01
[4]
Services > molecular and immunological diagnosis of several
diseases related with veterinary medicine, canine and equine
paternity testing, avian molecular sexing
Core technologies > molecular biology, DNA technologies
Target markets > veterinary and food industries
Main clients > veterinary hospitals and clinics, zoological parks,
cattle explorations, hipism centers, enterprises connected with
veterinary, food industry
[4]
Products > Natural anti-oxidants and colourants from
non-genetically modified microorganisms
Services > Bioprocess development and optimization contract
research
Core technologies > Fermentation technology using conventional
and non-conventional microorganisms, bioreaction engineering
Target markets > Food and feed industry;
cosmetics; pharmaceuticals
Facilities > State-of-the art equipped lab-scale facilities (battery of
bioreactors with automatic sampling, analytical equipment)
Pilot facilities > Access to pilot facilities through partnerships with
[5]
Company Profile
“DNA and other technologies applied to veterinary medicine and
food.”
24
Portuguese Biotechnology
DIRECTORY
CROs and industries
Main clients > Food and feed formulators
Technological relationships > Instituto Superior Técnico, Portugal;
TNO, The Netherlands
Other relevant partnerships > Concessus, Portugal
[5]
Company Profile
“BioTrend carries out its own research and develops in-house
projects aiming at the production of high value biomolecules and
also offers consulting and contract research services in the field of
Industrial Biotechnology.
In-house projects: BioTrend has developed a novel process for
the production of natural beta-carotene using naturally occurring
micro-organisms. BioTrend’s highly reproducible and scalable
process conveys major competitive advantages over alternative
natural beta-carotene production processes. It is the first
technology using non-genetically modified bacteria for the
production of carotenoids and enables BioTrend to offer a natural
product with all the technological and functional characteristics
of the established synthetic one. Pilot scale implementation is
under way. Industrial Biotechnology consultancy and contract
research: Examples of past contract R&D include the development
of a process for L-lactic acid production from cheese whey (Patent
PT102526) and the performance assessment of a whole-cell
biotransformation process for a leading specialty chemical
company.”
25
Portuguese Biotechnology.
[1]
Life above all.
[1]
BLUEPHARMA
CASTRO, PINTO & COSTA
Indústria Farmacêutica, SA
Castro, Pinto & Costa, Lda
> ADDRESS: Rua da Bayer, S. M. do Bispo > ZIP CODE: 3045-016 > CITY: COIMBRA
> ADDRESS: Rua Hintze Ribeiro, 585 - Sala 301 > ZIP CODE: 4450-692 > CITY: LEÇA DA PALMEIRA
> PHONE: +351 239 800 300 > FAX: +351 239 800 333 > EMAIL: [email protected] > WEB SITE: www.bluepharma.pt
> PHONE: +351 229 952 036 > FAX: +351 229 952 036 > EMAIL: [email protected] > WEB SITE: www.cpc.com.pt
> PERSON TO BE CONTACTED: Paulo Barradas Rebelo
> PERSON TO BE CONTACTED: Daniel Pinto
[2]
Area of Biotech Activities
Health, Medical, Diagnostics
[3]
Type of activity > Products and/or technologies from own R&D
> Contract research > Services > Commercialisation/distribution
of third party products
Start up (year) > 2001
Structure of the capital > Public limited company
Percentage owned by founders > 100%
Turnover (2005): 7,5 Million EUR
Foreign revenue (%turnover 2005): 50%
Total number of employees: 120
PhD: 1 > Master of Science: 5 > Graduate: 30
Percentage of employees involved in R&D Activities: 10%
R&D Expenses (% turnover 2005) > 10%
Number of national patents
Submitted: 01
[4]
Products > Acarbose, Losartan, Clarithromycin, Ramipril, Losartan/
HCTZ
Services > R&D, Contract-manufacturing and Sales
Core technologies > Development and manufacturing of solid
dosage forms; development of lipid-based nanoparticles
Target markets > Pharmaceutical industry
Facilities > Portugal
Pilot facilities > Portugal
Main clients > Helm, Merck, Biogaran, Sandoz, Stada
and Ratiopharm
Other relevant partnerships > INETI, ITN, Center for Neurosciences
and Cell Biology, Univ. Minho, Univ. Coimbra
26
[5]
Company Profile
“Bluepharma is a pharmaceutical Company of Portuguese
ownership, located in Coimbra. It is based on the excellence of its
production plant acquired to Bayer (which may be considered one
of the most advanced and well-designed in the country) as well as
on the quality and know-how of its employees and on the
experience and dynamism of its management team.
Bluepharma main areas of activity include:
* Contract-manufacturing of solid dosage forms
* R&D (nanotechnology-based approaches for protein and drug
delivery, sustained released formulations, formulation
development, analytical development, pilot batches production
and stability studies)
* Commercialisation of Generic medicines in Portugal
Bluepharma is a certified company (quality, environment and
ocuppational health and safety), fully devoted to
internacionalization, innovation, flexibility and competence.
Our commercial activity started in October 2003 and is supported
by 26 Commercial Representatives promoting the sales of
25 molecules in the Portuguese market (medical doctors and
Pharmacies).”
[2]
Area of Biotech Activities
Food Biotechnology, Nutrition Science > Health, Medical,
Diagnostics > Classical Fermentation, Bioprocess Technology
> Agricultural Biotechnology > Bioinformatics
[3]
Type of activity > Products and/or technologies from own R&D
> Contract research > Services > Commercialisation/distribution
of third party products
Start up (year) > 2000
Structure of the capital > Private limited company
Percentage owned by founders > Daniel Pinto - 30 % > Inês de
Castro 30 % > António Costa: 30 %
Turnover (2005): 17.257 EUR
Total number of employees: 7
Master of Science: 1 > Graduate: 7
Percentage of employees involved in R&D Activities: 30%
R&D Expenses (% turnover 2005) > 5%
Number of national patents:
Submitted: 01
safety area. It has been on the market for 6 years now and has been
expanding its activities. The core-business of the company is food
safety and food processing consultancy and R&D projects.
In the R&D department several projects are taking place in the
areas of Information Technologies applied to the fodd industry
(e.g. traceability software) and the exploitation of residues of food
industry processes to produce high added value products
Moreover, it produces and distributes Oleo Test ™ and other
products for the food and medical industry.
The Castro, Pinto & Costa, Lda. team is constituted by highly skilled
professionals with continuous training in their field of activity.”
[4]
Products > OleoTest
Services > Quality and Food Safety Consulting
Target markets > Food Industry; Medical
Industry
Pilot facilities > University of Minho
Main clients > EUREST Portugal, Filta Fry, ASAE, SOGENAVE
Technological relationships > University of Minho - Portugal
Other relevant partnerships > Derovo - Portugal
[5]
Company Profile
“Castro, Pinto & Costa, Lda. is a Portuguese Spin-off company
specialized in food industry, namely in food processing and food
Portuguese Biotechnology
DIRECTORY
27
Portuguese Biotechnology.
Life above all.
[1]
[1]
CRIOESTAMINAL
CYTOTHERA
SAÚDE E TECNOLOGIA, SA
Companhia Portuguesa de Investigação e Serviços em Biotecnologia Clínica, S.A.
> ADDRESS: Rua Pedro Nunes, Ipn > ZIP CODE: 3030-199 > CITY: COIMBRA
> ADDRESS: Rua Henrique Paiva Couceiro, nº 27, Venda-Nova > ZIP CODE: 2700-451 > CITY: AMADORA
> PHONE: +351 239 700 377 > FAX: +351 239 700 378 > EMAIL: [email protected] > WEB SITE: www.crioestaminal.pt
> PHONE: +351 214 997 500 > FAX: +351 214 997 509 > EMAIL: [email protected] > WEB SITE: www.cytothera.pt
> PERSON TO BE CONTACTED: Raul Santos
> PERSON TO BE CONTACTED: Sílvia Matos
with Portuguese and foreign research laboratories in order to
enlarge the field of therapeutic applications for stem cells from
umbilical cord blood.”
[2]
Area of Biotech Activities
Health, Medical, Diagnostics
[3]
Type of activity > Services
Start up (year) > 2005
Structure of the capital > Public limited company
Percentage owned by founders > Grupo Medinfar
Total number of employees: 9
Graduate: 7
[3]
Type of activity > Services
Start up (year) > 2003
Structure of the capital > Public limited company
Percentage owned by founders > 12 shareholders
Total number of employees: 11
PhD: 1 > Master of Science: 2 > Graduate: 7
Percentage of employees involved in R&D Activities: 20%
R&D Expenses (% turnover 2005) > 93%
[4]
Products > Clinical Biotech Services (Cell Therapy and Processing
and Storage of Stem Cells)
Services > Processing and Storage of Stem Cells from Umbilical
Cord Blood and Bone Marrow, Cell Therapy Services using Stem
Cells from Bone Marrow
Core technologies > Isolation of stem cells from umbilical cord
blood and bone marrow by ultracentrifugation and storage in
liquid nitrogen (vapour phase). Stem cells samples analyse by flow
cytometry and microbiologic control.
Facilities > Office and GMP laboratory
Main clients > Public and health professionals
Technological relationships > Cells4Health (The Netherlands),
Biovault (UK)
Other relevant partnerships > Grupo Medinfar and
EcBio- Portugal
[4]
Services > Cord Blood stem cells cryopreservation
Facilities > Crioestaminal Labs - Parque Tecnológico de Cantanhede,
Nucleo 04, Lote 3
Main clients > Parents-to-be
Technological relationships > Cryo-Save Labs (Belgium); Biosafe
(Switzerland)
[5]
Company Profile
“Crioestaminal - Saúde e Tecnologia, SA is a biotechnology
company which provides health services. It was created by a group
of professionals and companies from the field of Health.
Crioestaminal gives parents of newborns the possibility of isolating
and cryopreserving stem cells (link) from umbilical cord blood.
These cells can differentiate into several kinds of cells, and can
also renew and divide themselves indefinitely. Cryopreservation of
stem cells from umbilical cord blood aims at their potential future
use in the treatment of a number of diseases during the lifetime of
both the newborn itself and of its relatives.
Crioestaminal is also interested in developing research projects
28
[2]
Area of Biotech Activities
Health, Medical, Diagnostics
[5]
Company Profile
“Cytothera is a Clinical Biotech company providing two types of
services: Cell Therapy Services and Services related with
Processing and Storage of stem cells (both from umbilical cord
blood and bone marrow). Cytothera is also involved in several
areas of Cell Therapy Research.”
Portuguese Biotechnology
DIRECTORY
29
Portuguese Biotechnology.
Life above all.
[1]
[1]
ECBIO
EUROTRIALS
Investigação e Desenvolvimento em Biotecnologia, S.A. / R&D in Biotechnology
Consultores Científicos S.A.
> ADDRESS: Laboratório 4.11, Edifício IBET/ITQB, Apartado 98 > ZIP CODE: 2781-901 > CITY: OEIRAS
> ADDRESS: Rua Tierno Galvan Torre 3-Piso 16 > ZIP CODE: 1070-274 > CITY: LISBOA
> PHONE: +351 214 469 467 > FAX: +351 214 469 364 > EMAIL: [email protected] > WEB SITE: www.ecbio.com
> PHONE: +351 213 825 440 > FAX: +351 213 825 452 > EMAIL: [email protected] > WEB SITE: www.eurotrials.com
> PERSON TO BE CONTACTED: Helder Cruz / Pedro Cruz
> PERSON TO BE CONTACTED: Rui Melo
[2]
Area of Biotech Activities
Classical Fermentation, Bioprocess Technology > Health, Medical,
Diagnostics
[3]
Activity > ECBio is a biotech company active in the development
of products and technologies involving the use of human and
mammalian cells in the areas of cell therapy and biological cell
based assays for diagnostic and individual drug
Type of activity > Products and/or technologies from own R&D
> Contract research > Services
Start up (year) > 1999
Structure of the capital > Public limited company
Total number of employees: 8
PhD: 4 > Graduate: 4
Percentage of employees involved in R&D Activities: 90%
R&D Expenses (% turnover 2005) > 150%
Number of national patents:
Submitted: 03 > Awarded: 02
Number of International patents:
Submitted: 01
UK, DE, FR, Companies all over the world
[5]
Company Profile
“ECBio is a biotech company active in the development of
products and technologies involving the use of human and
mammalian cells in the areas of cell therapy and biological cell
based assays for diagnostic and individual drug testing.
ECBio’s activity is based on the specific know-how in the area of
animal cell culture in general and in human cells in particular,
being organized in two different business areas: cell therapy and
cell based assays.
ECBio is currently developing two cell therapy protocols: one in the
area of spinal cord injury and one in the area of bone
regeneration applied to tooth implants. ECBio is also collaborating
in the development of a bioartifical pancreas for the treatment of
type I diabetic patients.
In parallel, ECBio has been developing technologies in the area of
in vitro cell based assays, having developed tests for cytotoxicity,
antitumoral activity and drugs efficacy.”
[4]
Products > Serum-free and protein-free cell culture media
Services > Cell-based assays; cell processing
Core technologies > Human and animal cell therapies, inlcuding
somatic and adult stem cells
Target markets > Biomedical and Pharmaceutical sectors
Facilities > Two R&D laboratories for cell processing, cell culture
and analysis
Pilot facilities > Acess to the pilot facilities of a collaborating
private company and of an institute
Main clients > Biomedical and pharmaceutical companies as well
as hospitals and clinics
Technological relationships > Hospitals in IT DE FR, Institutes in
30
[2]
Area of Biotech Activities
Health, Medical, Diagnostics > Food Biotechnology, Nutrition
Science > Bioinformatics
[3]
Activity > Research Services and Scientific Consulting in the Health
Sector
Type of activity > Contract research > Services
Start up (year) >1994
Structure of the capital > Public limited company
Percentage owned by founders > 70%
Turnover (2005): 3,7 Million EUR
Foreign revenue (%turnover 2005): over 75%
Total number of employees: 70
PhD: 3 > Master of Science: 4 > Graduate: 58
Percentage of employees involved in R&D Activities: 90%
the Medical Community and the Pharmaceutical Industry,
providing clinical research services and scientific consulting in the
Health sector.
The company is present in Brazil since 1998, where it has an
operation with 30 professionals currently expanding its activities
to other countries in Latin America. It is also developing projects in
Africa, namely in Angola and Mozambique.
The company is ISO 9001:2000 certified by Lloyd’s Register Quality
Assurance with the UKAS (UK Accreditation Service).
Eurotrials has developed globally more than 800 projects in all
major therapeutic areas, using conventional drugs,
biotechnology products and medical devices, involving more than
350.000 subjects in clinical trials and epidemiological studies.”
[4]
Services > Research Methodology Consultancy, Translational
Research, Clinical Research, Regulatory Affairs, Data Management
and Biostatistics. Epidemiology, Functional Foods and Nutritional
Studies. Quality Assurance Services and Teaching Programs.
Healtheconomics.
Target markets > Pharmaceutical, biotech and agro-food industry,
health institutions, academia, international organizations and
foundations promoting clinical research
Facilities > Head office in Lisbon (Portugal) and subsidiary in S.Paulo
(Brazil)
Main clients > Pharmaceutical and Biotech Industry (mainly EU
and US based), R&D Institutions, CROs, Agro-Food Industry
[5]
Company Profile
“Eurotrials is the leading Contract Research Organizarion (CRO)
founded in Portugal (Lisbon), in 1994 by members of Academia,
Portuguese Biotechnology
DIRECTORY
31
Portuguese Biotechnology.
Life above all.
[1]
[1]
FOODMETRIC
GENE EXPRESS
Foodmetric, SA
Serviços Genómicos para Investigação e Diagnóstico Lda
> ADDRESS: Pavilhão 1 - campus Universitário de Santiago > ZIP CODE: 3810-193 > CITY: AVEIRO
> ADDRESS: Taguspark; Núcleo Central 30 > ZIP CODE: 2780-920 > CITY: OEIRAS
> PHONE: +351 234 380 303 > FAX: +351 234 421 748 > EMAIL: [email protected] > WEB SITE: www.foodmetric.com
> PHONE: +351 968 766 088 > FAX: +351 210 187 807 > EMAIL: [email protected] > WEB SITE: www.gene-express.eu
> PERSON TO BE CONTACTED: Ana Daniel
> PERSON TO BE CONTACTED: Jörg Becker
[2]
Area of Biotech Activities
Food Biotechnology, Nutrition Science > Agricultural
Biotechnology > Environmental Biotechnology > Classical
Fermentation, Bioprocess Technology
leading factor in our company since it enables us to develop new
and innovative products and services. Thus, several bonds with
universities and research centers have been established, in order to
allow the access to state-of-art technologies.”
[3]
Type of activity > Products and/or technologies from own R&D
> Contract research > Services
Start up (year) > 2004
Structure of the capital > Private Limited Company
Percentage owned by founders > 100%
Total number of employees: 2
PhD: 2
[3]
Type of activity > Products and/or technologies from own R&D
> Services
Start up (year) > 2006
Structure of the capital > Public limited company
Percentage owned by founders > Venture capital: 30%; University
of Aveiro: 30%; Others: 35%
Total funds raised > 215.000 EUR
Total number of employees: 6
PhD: 5 > Graduate: 1
Percentage of employees involved in R&D Activities: 50%
R&D Expenses (% turnover 2005) > 20%
play a fundamental role in basic research and pharmacogenomics
with applications ranging from whole-genome gene expression
profiling over large-scale genotyping to resequencing and are
developing into important new diagnostic tools in the health care
and agro-food sector.
Gene Express supports this development in Portugal and
neighbouring countries.”
[4]
Services > Services based on high-density DNA array technology
for: Gene Expression Analysis and Large-scale Genotyping;
Contract Research; Data Analysis and Consulting
Target markets > Health Care sector,
Pharmaceutical industry, Agro-Food sector, Academics
Facilities > Affymetrix GeneChip Facility in the Instituto Gulbenkian
de Ciência, Oeiras
Technological relationships > Affymetrix UK Limited
[4]
Products > Rapid methods for the analysis of food products that
may include software components: OliveoilPack, CerealPack,
JuicePack
Services > Consultance, Tecnical assistance
Core technologies > Software platform that enables data analysis
and data mining of a large volume of information.
Target markets > Food and Drink companies
Facilities > Lab and administrative office
Technological relationships > University of Aveiro - Portugal
[5]
Company Profile
“Gene Express Lda is located in Taguspark (Oeiras) and was
founded in the year 2004 by scientists of the Instituto Gulbenkian
de Ciência (Oeiras) and the Instituto Superior Técnico (Lisbon).
It provides expert services for research and diagnostics including
contract research, based on Affymetrix high-density DNA array
(GeneChip®) technology, and is committed to the development of
new diagnostic DNA arrays tailored to specific health care needs.
Gene Express is Portugal’s authorized Affymetrix service provider
and its team looks back on more than four years of practical
experience with GeneChip® technology. High-density DNA arrays
[5]
Company Profile
“FoodMetric is a company that will provide solutions to food and
drink companies through the implementation of fast and reliable
methods to perform food analysis, by replacing the conventional
methods of analysis by instrumental ones. Innovation is the
32
[2]
Area of Biotech Activities
Gene-based Bioindustries > Health, Medical, Diagnostics
> Bioinformatics
Portuguese Biotechnology
DIRECTORY
33
Portuguese Biotechnology.
Life above all.
[1]
[1]
GENE PREDIT
GENEBOX
Gene Predit, Lda
Desenvolvimento e Produção de Testes de Diagnóstico, Lda
> ADDRESS: BIOCANT PARK - Parque Tecnológico de Cantanhede, Núcleo 04, Lote 3 > ZIP CODE: 3060-197 > CITY: CANTANHEDE
> ADDRESS: Rua Pedro Nunes - Quinta Da Nora > ZIP CODE: 3030 - 199 > CITY: COIMBRA
> PHONE: +351 939 320 693 > FAX: +351 231 410 893 > EMAIL: [email protected]
> PHONE: +351 239 700 930 > FAX: +351 239 700 930 > EMAIL: [email protected] > WEB SITE: www.genebox.com
> PERSON TO BE CONTACTED: Nuno Faustino or Joana Branco
> PERSON TO BE CONTACTED: Paulo Santos
[2]
Area of Biotech Activities
Health, Medical, Diagnostics > Gene-based Bioindustries
[2]
Area of Biotech Activities
Health, Medical, Diagnostics
[3]
Activity > Gene PreDiT, Lda. is a biotechnology company launched
in 2006 focused in expanding the concept of Personalized
Medicine in Portugal. To do so, Gene PreDiT will introduce new and
broader diagnostic/preventive methods in the market.
Type of activity > Services > Commercialisation/distribution of
third party products
Start up (year) > 2006
Structure of the capital > Private limited company
Percentage owned by founders > 100%
Total funds raised > 100.000 EUR
Total number of employees: 2
PhD: 2
Percentage of employees involved in R&D Activities: 100%
[3]
Activity > Conception, development and production of diagnostic
tests
Type of activity > Products and/or technologies from own R&D
> Contract research > Services
Start up (year) > 2003
Structure of the capital > Private limited company
Percentage owned by founders > Inopat, SA - 75%; Others - 25%
Total funds raised > 242.000 EUR
Total number of employees: 6
PhD: 1 > Master of Science: 1 > Graduate: 4
Percentage of employees involved in R&D Activities: 67%
[4]
Products > Cytokines; HLA; PCR Kits
Services > Courses in molecular biology techniques
Target markets > Diagnostics and investigation
[5]
Company Profile
“Gene PreDiT, Lda. is a biotechnology company launched in 2006
focused in expanding the concept of Personalized Medicine in
Portugal and giving a higher relevance to prevention.
Taking advantage of the Human Genome Project and HapMap,
it will be possible to develop tests that will distinguish those who
have a genetic susceptibility to a certain disease from those who
do not have that susceptibility. This will allow a better health care
management of both patients and practitioners, since patients will
be directed to specialists according to their risk profile.”
34
NP EN ISO 13485:2004 for Quality Management Standard for In
Vitro Diagnostic (IVD) Medical Devices and council
Directive 98/79/EC on In-Vitro Diagnostic (IVD) Medical Devices.”
[5]
Company Profile
“Founded in 2003, geneBOX is a company dedicated to the
conception, development and production of diagnostics tests,
exclusively oriented towards molecular biology investigation
laboratories. geneBOX is part an enterprise Group (IPN) and has 75
sq mtr of floor space, divided between the areas of Quality Control
(50 sq mtr) and production (25 sq mtr).Currently the company has
6 employees, with experience and technical skills to respond to the
competitive molecular biology market, in which geneBOX belongs.
geneBOX is constantly updating the personnel and equipment
in response to the most recent conception, development and
production techniques. geneBOX is the first Portuguese
biotechnology company to hold the certification according to the
Portuguese Biotechnology
DIRECTORY
35
Portuguese Biotechnology.
[1]
Life above all.
[1]
GENELAB
GENETEST
Diagnóstico Molecular Sociedade Unipessoal, Lda
Prestação de Serviços de Testes de Diagnóstico, S.A.
> ADDRESS: Rua Pedro Nunes, IPN > ZIP CODE: 3030-199 > CITY: COIMBRA
> ADDRESS: Rua do Campo Alegre, 823 > ZIP CODE: 4150-180 > CITY: PORTO
> PHONE: +351 239 700 367 > FAX: +351 239 700 368 > EMAIL: [email protected] > WEB SITE: www.genelab.pt
> PHONE: +351 226 074 949 > FAX: +351 226 099 157 > EMAIL: [email protected] > WEB SITE: www.genetest.pt
> PERSON TO BE CONTACTED: Raul Santos
> PERSON TO BE CONTACTED: Mariana Americano
[2]
Area of Biotech Activities
Health, Medical, Diagnostics
[2]
Area of Biotech Activities
Health, Medical, Diagnostics > Gene-based Bioindustries
[3]
Type of activity > Products and/or technologies from own R&D
> Services
Start up (year) > 2006
Structure of the capital > Private limited company
Percentage owned by founders > 100%
Total number of employees: 3
PhD: 1 > Graduate: 2
Percentage of employees involved in R&D Activities: 67%
[3]
Activity > Services of diagnostics genetic tests
Type of activity > Services
Start up (year) > 2004
Structure of the capital > Public limited company
Percentage owned by founders > José Carlos Lemos Machado
(7,5%), Maria do Céu Fontes Herdeiro Figeiredo (3,5%), Paulo Jorge
Sales Vaz Canedo (3,5%), Maria de Fátima Machado Henriques
Carneiro (0,25%), Manuel Alberto Coimbra Sobrinho Simões
(0,25%), António Barroca (10,5%)
Turnover (2005): 6.848 EUR
Total number of employees: 1
PhD: 1
Percentage of employees involved in R&D Activities: 100%
[4]
Services > Molecular diagnostic tests for disease management
and prevention
Core technologies > molecular analysis of fetal DNA in maternal
plasma of pregnant women
Target markets > health intervenients
Facilities > Molecular Biology laboratory
Main clients > private clients, clinicians, hospitals
Technological relationships > Genetics Clinic, Faculty of Medicine,
University of Coimbra
Other relevant partnerships > Biocant Park
[4]
Services > Diagnostics genetic tests
Target markets > Hospitals and final client
Facilities > Portugal
Pilot facilities > Portugal
Main clients > Hospital S. João do Porto
Technological relationships > IPATIMUP (Portugal)
[5]
Company Profile
“Genelab is a molecular diagnostic laboratory offering services in the
areas of Infectious diseases, Oncology and Genetics. Main tests are
based on nucleic acid analysis such as real time PCR, fragment
analysis and microchips. In partnership with the Genetics Clinic,
Faculty of Medicine from the University of Coimbra, a test for fetal sex
determination from maternal blood was developed and is already in
the market. New tests based on fetal genome analysis on plasma from
pregnant women will be available in the near future.”
36
[5]
Company Profile
“Genetest’s mission is to develop and offer services based on new
tests to genetic diseases. The company wishes to help its clients in
discovering if they are susceptible to those diseases.”
Portuguese Biotechnology
DIRECTORY
37
Portuguese Biotechnology.
[1]
Life above all.
[1]
GENIBET BIOPHARMACEUTICALS
GENOMED
Genibet Biopharmaceuticals, SA
Diagnósticos de Medicina Molecular, SA
> ADDRESS: Edifício da Instalação Piloto do IBET, Avenida da República, Quinta do Marquês > ZIP CODE: 2781-901 > CITY: OEIRAS
> ADDRESS: Av. Prof. Egas Moniz, Edifício Egas Moniz, Sala P3 - A - 23 > ZIP CODE: 1649 - 028 > CITY: LISBOA
> PHONE: +351 214 469 482 > FAX: +351 214 469 390 > EMAIL: [email protected] > WEB SITE: www.genibet.eu
> PHONE: +351 217 999 501/06 > FAX: +351 217 999 500 > EMAIL: [email protected] > WEB SITE: www.genomed.pt
> PERSON TO BE CONTACTED: João Miranda Reis (CEO), Manuel Carrondo (CSO), Luís Paulo Rebelo (Executive Director)
> PERSON TO BE CONTACTED: Joana Perdigão
[2]
Area of Biotech Activities
Classical Fermentation, Bioprocess Technology > Technology
Transfer, IPRs > Gene-based Bioindustries
[3]
Activity > Process and Assay Development, GMP cell
banking, Microbial and mammalian cells fermentation, Cell Culture
Clarification, Chromatography, High pressure homogenization
with refrigeration, Viral Clearance, Ultrafiltration and Diafiltration,
Custom Process Steps
Type of activity > Contract Manufacturing
Start up (year) > 2006
Structure of the capital > IBET (45%), Nutrinvest, Medinfar, CIPAN
and PME Capital (10% each), Lusomedicamenta, Tecnifar and Lef
(5% each)
Total funds raised > 5,3 Million EUR
Foreign revenue (%turnover 2005): 100% in cruise speed,
estimated at 3,5 Million EUR
Total number of employees: 2
PhD: 1 > Graduate: 1
Percentage of employees involved in R&D Activities: R&D
required is outsourced
[5]
Company Profile
“Biopharmaceutical contract manufacturing company, offering
comprehensive cGMP services for proteins, virus and plasmid DNA,
from pre-clinical to Phase II clinical trials, including:
Upstream and Downstream Process Development
Optimization and Scale-Up for different expression systems
(mammalian, microbial, virus)
cGMP Cell Banking
cGMP Contract Manufacturing
Viral Clearance
Assay Development
Quality Control and Quality Assurance
Regulatory Compliance”
[3]
Type of activity > Contract research > Services
Start up (year) > 2004
Structure of the capital > Public limited company
Total funds raised > 1 Million EUR
Total number of employees: 12
PhD: 3 > Master of Science: 3 > Graduate: 6
Percentage of employees involved in R&D Activities: 50%
GenoMed´s strategy focuses on: Using the most recent methods
and technologies, according to international standards;
recruiting highly specialized scientists and technicians with a
strong background in the relevant fields; establishing close
relations with clinicians from the relevant medical areas;
implementing a very strict program of Quality Control and
participating in External Quality Assessment programs .”
[4]
Services > Molecular Diagnosis
Target markets > Hospitals, Health Care Industries
(Private hospitals, Clinics etc)
Main clients > Hospitals
Technological relationships > IMM - Institute of Molecular Medice
[5]
Company Profile
“GenoMed is a start-up company founded in October 2004, as
the result of an innovative project promoted by the Institute of
Molecular Medicine, where it is situated.
The mission of GenoMed is to continuously integrate scientific and
technological knowledge in the development and providing of
the newest and best molecular diagnostic testing methods.
GenoMed´s main objectives are: To provide the best and most
up-to-date molecular diagnostic tests with a strong commitment
to quality; promote and participate in Translational Research
projects that assure the incorporation of scientific and
technological developments into the clinical practice; develop
molecular diagnostics methods with impact on the clinical
management of patients.
[4]
Services > Process and Assay Development, Technology Transfer,
Process Scale-up and cGMP Manufacturing for APIs of new
biopharmaceuticals, from pre-clinical to Phase II clinical trials,
under contract
Target markets > biopharmaceutical industry
Facilities > 2 suites designed to comply with BL1 and BL2 and
quality control; total area of 450 sq.m.
Main clients > Commercial operation planned to start by mid 2007
Technological relationships > IBET, Portugal
Other relevant partnerships > Partnerships with other Contract
Manufacturing Organizations and international companies in the
biopharmaceuticals area under development
38
[2]
Area of Biotech Activities
Health, Medical, Diagnostics > Technology Transfer, IPRs
Portuguese Biotechnology
DIRECTORY
39
Portuguese Biotechnology.
Life above all.
[1]
[1]
HALORIS
IMUNOSTAR
Nanotecnologias
Investigação e Comercialização de Produtos de Biodiagnóstico, SA
> ADDRESS: Biocant Park, Associação Beira Atlântico Parque, Núcleo 4, Lote 2 > ZIP CODE: 3060-197 > CITY: CANTANHEDE
> ADDRESS: Rua Campo Alegre, 823 > ZIP CODE: 4150-180 > CITY: Porto
> PHONE: +351 217 500 228 > FAX: +351 217 500 172 > EMAIL: [email protected] > WEB SITE: www.haloris.com
> PHONE: +351 226 074 950 > FAX: +351 226 099 157 > EMAIL: [email protected] > WEB SITE: www.imunostar.pt
> PERSON TO BE CONTACTED: Hugo Ferreira
> PERSON TO BE CONTACTED: Pedro Seada
[2]
Area of Biotech Activities
Health, Medical, Diagnostics > Food Biotechnology, Nutrition Science > Environmental Biotechnology
[3]
Activity > Services, R&D in Biotechnology and Nanotechnology
Type of activity > Products and/or technologies from own R&D
> Contract research > Services
Start up (year) > 2006
Structure of the capital > Private limited company
Percentage owned by founders > 100%
Total number of employees: 3
Graduate: 2
Percentage of employees involved in R&D Activities: 100%
Number of International patents:
Submitted: 01
[4]
Products > Technology of portable biosensors and biological
assays development (to license or sell as own products)
Services > Consulting in Biosensors and Nanotechnology;
surface functionalisation and spotting of microstructures
Core technologies > Magnetic sensors technology for
biodetection
Target markets > Agrifood (food quality control) and Healthcare
(diagnostics)
Facilities > Laboratory at ICAT
Technological relationships > Biocant
(Cantanhede, Portugal); ICAT-FCUL (Lisboa, Portugal); Instituto
Superior de Ciências da Saúde Egas Moniz (Lisboa, Portugal);
INESC-MN (Lisboa, Portugal); INESC-ID (Lisboa, Portugal)
40
[5]
Company Profile
“Haloris Nanotecnologias is a portuguese start-up company, which
started its activity in July, 2006. It is a R&D company involved in the
development, prototyping and commercialization of portable
biosensors for the agrifood, environmental and healthcare sectors.
Its core technology is based on magnetic sensing of biomolecular
interactions such as DNA hybridization and antibody-antigen
recognition. This technology enables sensitive and multiplexed
biological analysis at point-of-care settings.
Research efforts are focused on system integration, surface
chemistry and labelling. Furthermore, the company also offers
services on consulting on biosensors and nanotechnology and
contract development of biological assays.
Haloris Nanotecnologias has already established partnerships
with national biotechnology, clinical and microelectronics
research institutes for developing portable microbiological
analysis systems. Presently, the company is searching for
international scientific, industrial and financial partners in the
areas of application development, commercialisation and
investment.”
[2]
Area of Biotech Activities
Health, Medical, Diagnostics
[3]
Activity > Development and commercialisation of diagnostic tests
Type of activity > Products and/or technologies from own R&D
> Commercialisation/distribution of third party products
Start up (year) > 2004
Structure of the capital > Public limited company
Total number of employees: 2
Master of Science: 1 > Graduate: 1
[4]
Products > Innovative diagnostic tests for health diseases and
certain clinical conditions
Services > Commercial and marketing developmet
Target markets > Clinical and Laboratory Diagnostic market
Facilities > IBMC; Biocodex
Main clients > Hospitals, clinics, pharmacies
Technological relationships > INETI, IHMT, Portugal
Other relevant partnerships > PREGENESYS European Consortium
Project
[5]
Company Profile
“ImunoSTAR is a clinical diagnostic company.
The main goal is to develop new diagnostic tests for health
diseases and other clinical conditions, through contract research
with national R&D institutes and commercialisation of third party
products.”
Portuguese Biotechnology
DIRECTORY
41
Portuguese Biotechnology.
[1]
Life above all.
[1]
INTRANSTEC
ITB
Intermediação e Transferência de Tecnologia, unipessoal
Investigação e Transferência de Biotecnologia, Lda
> ADDRESS: Campo pequeno 2, 10ºA > ZIP CODE: 1000-078 > CITY: LISBOA
> ADDRESS: Rua Câmara Pestana 21, 1º, sala 4 > ZIP CODE: 9000-043 > CITY: FUNCHAL
> PHONE: +351 217 942 014 > FAX: +351 217 942 016 > EMAIL: [email protected] > WEB SITE: www.intranstec.com
> PHONE: +351 291 280 664 > FAX: +351 291 280 664 > EMAIL: [email protected] > WEB SITE: www.itb.co.pt
> PERSON TO BE CONTACTED: Alexandra Galamba
> PERSON TO BE CONTACTED: Pedro Diniz
[2]
Area of Biotech Activities
Technology Transfer, IPRs
products or technological platforms and those that are actively
looking to license or acquire new opportunities to complete their
portfolio or to ameliorate their technological stand.”
[3]
Activity > ITB is currently engaged in managing an agricultural
farm, providing food safety consulting services to a fish processing
unit, managing a fishery’s technology project, developing an
eco-tourism internet site and providing on-site data collecting
services for artificial sea reef construction and environmental water
quality monitoring. Previously the company has managed a sea
bream fish farm and two biodiversity data base projects, Atlantis
and Biodiversidade.net, funded throw Interreg III B and POSI.
Type of activity > Services
Start up (year) > 2002
Structure of the capital > Private limited company
Percentage owned by founders > 100%
Total number of employees: 1
Graduate: 1
[3]
Type of activity > Services
Start up (year) > 2000
Structure of the capital > Private limited company
Percentage owned by founders > 100%
Turnover (2005): 104.000 EUR
Total number of employees: 2
PhD: 1 > Graduate: 1
[4]
Services > Technology and product transfer service in area of the
Life Sciences, focusing on Pharmaceuticals and Biotechnology
Target markets > Pharmaceutical and Biotechnology
Main clients > Small and Middle-size pharmaceutical, medical
devices and biotechnology companies. Research Institutes.
[4]
Services > Biology consultancy in R&D technology projects, mainly
related to sea subjects. The company can offer project
management expertise with experience in Portuguese, Spanish
and English written projects, food safety consultancy and
environmental services.
Target markets > Fisheries, aquaculture,
agriculture/agro-industries
Facilities > Office at Rua Câmara Pestana 21, 3º, sala 14
Main clients > Diecção Regional das Pescas da Madera, Direcção
Regional do Ambiente da Madeira, Exploração Agricola Quinta
Santa Luzia, Lda e Francisco Nascimento e Filhos, SA
Technological relationships > BIO3 - Estudos e Projectos em
Biologia e Valorização de Recursos Naturais, Lda.
[5]
Company Profile
“InTransTec is a technology transfer services company with
European dimension, operating from Portugal. The company focus
its activities on the Life Sciences field, mainly on the
Pharmaceutical and Biotechnology sectors. InTransTec has very
significant experience in fostering licensing and distribution deals
between technology/product originators and users, technology
transfer from institutional players, business development
consultancy, and scouting services for venture capital companies
and assistance in the identification of investment opportunities.
ITT helps building business bridges between those companies or
institutions that produce knowledge, both in the biotechnology
and pharmaceutical fields, that can be transformed into new
42
[2]
Area of Biotech Activities
Food Biotechnology, Nutrition Science
Portuguese Biotechnology
DIRECTORY
[5]
Company Profile
“ITB is a biology consulting company located in Madeira Island,
Portugal.
It was founded in November 2002 and is strategically positioned
to act as partner in R&D projects in biology and biology related
subjects.
Due to being one of the first private companies to work in science
and technology in Madeira, ITB won the Madeira Prize for
Enterprise Innovation 2003, awarded by CEIM (Madeira Enterprise
and Innovation Centre).
Main expertise in national/ international projects and research
activities: ITB is currently engaged in managing an agricultural
farm, providing food safety consulting services to a fish processing
unit, managing a fishery’s technology project,
developing an eco-tourism internet site and providing on-site data
collecting services for artificial sea reef construction and
environmental water quality monitoring.
Previously the company has managed a sea bream fish farm and
two biodiversity data base projects, Atlantis and Biodiversidade.
net, funded throw Interreg III B and POSI.”
43
Portuguese Biotechnology.
[1]
Life above all.
[1]
NECTON
PROENOL
Companhia Portuguesa de Culturas Marinhas, S.A.
Indústria Biotecnológica, Lda
> ADDRESS: Belamandil > ZIP CODE: 8700-152 > CITY: OLHÃO
> ADDRESS: Travessa das Lages, nº 267 > ZIP CODE: 4405-194 > CITY: VILA NOVA DE GAIA
> PHONE: +351 289 703 961 > FAX: +351 289 703 474 > EMAIL: [email protected] > WEB SITE: www.necton.pt
> PHONE: +351 227 150 840 > FAX: +351 227 150 849 > EMAIL: [email protected] > WEB SITE: www.proenol.com
> PERSON TO BE CONTACTED: João Navalho
> PERSON TO BE CONTACTED: Maria De Fátima Teixeira
[2]
Area of Biotech Activities
Food Biotechnology, Nutrition Science > Aquaculture, Coastal and
Marine Biotech
[3]
Type of activity > Products and/or technologies from own R&D
Start up (year) > 1997
Structure of the capital > Public limited company
Percentage owned by founders > 55%
Total funds raised > 200.000 EUR
Turnover (2005): 1 Million EUR
Foreign revenue (%turnover 2005): 55%
Total number of employees: 25
PhD: 1 > Master of Science: 1 > Graduate: 10
Percentage of employees involved in R&D Activities: 24%
R&D Expenses (% turnover 2005) > 10%
[4]
Products > PhytoBloom, a microalgae concentrate for aquaculture
hatcheries, nurseries, and ornamental fish production. Marine salt
in two products: traditional marine salt (extracted without any
processing); and flor de sal, a unique gourmet salt from the
evaporating brine layer during the summer.
Services > R&D services in the fields of Aquaculture Development
and Microalgae Biotechnologies. The services are developed either
as partners or sub- contracted in EC Projects, taking advantage of
the unique site specific and pilot plant facilities.
Core technologies > The microalgae are produced in
photobioreactor of different types: tubular and flat pannel flow
trough. It is possible to produce different microalgae in these
photobioreactors.
Target markets > Aquaculture and Cosmetics - Microalgae; Food
Sector - Salt and flor de sal
Facilities > Necton is located in a 14ha salt marsh, between the
cities of Faro and Olhão in the Natural Park of Ria Formosa, south of
Portugal
44
Main clients > The company develops the activity in two
completely different markets: PhytoBloom is sold mainly to
Aquaculture hatcheries, R&D institutions, Universities, and
ornamental fish products distributors; marine salt is sold for health
food chains, high quality supermarkets, gourmet restaurants and
other users of high quality salt.
Technological relationships > Agrotechnical Research Institute
(ATO-DLO), Netherlands; AquaTT - European Aquaculture Training
and Technology Transfer Network, Ireland; CEVA – Centre d’Etude
et Valorization des Algues, France; Liverpool John Moores
University, UK; Scottish Association for Marine Science (SAMS), UK;
University of Hull – Department of Biological Sciences, UK;
University of Plymouth - Fish Nutrition Unit - Department of
Biological Sciences, UK; University of Stirling - Institute of
Aquaculture, UK; Chinese Academy of Sciences, Department of
Photosynthesis and South China Sea Institute of Oceanology
- Academia Sinica, P.R. China; IMBC - Institute of Marine Biology of
Crete, Greece; Universidad de Santiago de Compostella Laboratorio de Microbiologia, Spain.
[5]
Company Profile
“Necton is a company specialised in microalgae production.
The available scientific, technological and market knowledge
involves applications for the Aquaculture, Agro-food, Health Food
and Cosmetic Sector. There is a wide expertise in carotenoids
(betacarotene, astaxantin…), poli-unsaturated fatty acids and
phycobiliproteins. Necton´s mission is to market innovative
products coming from scientific and technological knowledge in
Marine Biotechnologies. “
Portuguese Biotechnology
[2]
Area of Biotech Activities
Food Biotechnology, Nutrition Science
[3]
Activity > Proenol is a company specialised in the production of
encapsulated microrganisms. An industrial production process, unique
worldwide has been developed and currently there are different
products for winemaking available. PROENOL also commercialized an
entire range of products for Oenology, such as vinification, clarification,
stabilization, filtration and hygiene. PROENOL also has available to their
costumers a Costumer Support Office.
Type of activity > Products and/or technologies from own R&D
> Commercialisation/distribution of third party products
Start up (year) > 1986
Structure of the capital > Private limited company
Percentage owned by founders > 100% Privately owned
Turnover (2005): 3 Million EUR
Foreign revenue (%turnover 2005): 5%
Total number of employees: 22
Graduate: 11
Percentage of employees involved in R&D Activities: 14%
Number of national patents:
Submitted: 02 > Awarded: 02
Number of International patents:
Submitted: 02 > Awarded: 02
[4]
Products > ProElif® - Sparkling wines production in bottle –
Classical Method > ProCuvée® - Sparkling wines production in tank
– Closed Tank Method > ProRestart® - To restart stuck and sluggish
alcoholic fermentations > ProDessert® - To produce “Residual sugar
wines” > ProMalic® - Biological wine deacidification
Core technologies > The immobilized microorganisms have the
DIRECTORY
advantage of being easily introduced and removed from the culture
media after total or partial biotransformation of the substrates. One of
the commonly used techniques for the immobilization of microorganisms is inclusion, also called encapsulation: this consists in including the
microorganism in a rigid polymer matrix. The technological advances
related to these immobilization techniques have made inclusion
possible without any liberation of cells from the support media.
Target markets (sector/industry) > Winemaking
Facilities > Proenol has an industrial plant for production and
commercial facilities in Canelas – Vila Nova de Gaia
Technological relationships > Institut National Polytechnique de
Toulouse - École Nationale Supérieure des Ingénieurs en Arts Chimiques
Et Technologiques- Fraça Instituto Tecnológico e Nuclear - Portugal
Other relevant partnerships > Lallemand; Pall; Ecolab; Fordras;
Sofralab
[5]
Company Profile
“Starting its activity in 1986, PROENOL has defined its own philosophy:
to put Biotechnology at the service of Oenology and Winemaking.
PROENOL is a biotech industry which performance area is centred in
Oenology, enclosing vinification, clarification, stabilization, filtration and
hygiene. Proenol offers to its clients a permanent support both at pre
and post selling levels by its technicians, which are highly qualified.
The Value and Acknowledge of the technical quality of its products and
services is well established and demonstrated by its continuous growth
and strong financial effort in investments. PROENOL is supported by
several investigation projects, with several institutions, advisors and
internationally recognized investigators. Proenol’s tribute to the
oenology sector has been made at several levels. The innovation is
concern to the industrialisation of encapsulated yeasts production,
initially designed for the production of sparkling wines, and currently
with other applications: as stuck fermentations and biological
deacidification of the wine/must . ”
45
Portuguese Biotechnology.
Life above all.
[1]
[1]
SIMBIENTE
STAB VIDA
Engenharia e Gestão Ambiental, Lda.
Investigação e Serviços em ciências Biológicas Lda.
> ADDRESS: Praça Paulo Vidal, nº 21 > ZIP CODE: 4715-245 > CITY: BRAGA
> ADDRESS: Av. da República, Estação Agronómica Nacional, ITQII. Apartado 89, Sto António de Oeiras > ZIP CODE: 2781-601 > CITY: OEIRAS
> PHONE: +351 253 261 009 > FAX: +351 253 261 009 > EMAIL: [email protected] > WEB SITE: www.simbiente.com
> PHONE: +351 214 469 760 > FAX: +351 214 469 740 > EMAIL: [email protected] > WEB SITE: www.stabvida.com
> PERSON TO BE CONTACTED: Sérgio Costa
> PERSON TO BE CONTACTED: Orfeu Flores
[2]
Area of Biotech Activities
Environmental Biotechnology > Classical Fermentation, Bioprocess
Technology > Aquaculture, Coastal and Marine Biotech
[3]
Type of activity > Products and/or technologies from own R&D >
Contract research > Services
Start up (year) > 2004
Structure of the capital > Private limited company
Percentage owned by founders > 100%
Turnover (2005): 101.246 EUR
Total number of employees: 8
PhD: 1 > Graduate: 7
Percentage of employees involved in R&D Activities: 10%
Company Profile
“SIMBIENTE - Environmental Engineering and Management, Lda. is
a technological company, focused on research, development,
innovation and services in Environmental Engineering areas.
Resulting from activities of researchers from Department of
Biological Engineering, SIMBIENTE was founded in 2004 as a
spin-off company of University of Minho. The strategic and
operational policies of SIMBIENTE ascribe major interest on
procedures and actions concerning the development and
acquisition of new technologies, the knowledge and domain of
innovative processes, as well as the permanent staff updating
improving their creative ability and innovation capabilities.”
[4]
Products > Environmental and Sustainability Reporting; Strategic
and/or Operational Plans; Economic Analysis of Environmental
Resources and Risks; Market Tools; Advanced Training Courses
Services > Sustainability and Environmental Management;
Technologies and Pollution Control; Ecosystems Protection and
Valorization; Environmental Training and Communication;
Research and Development (R&D)
Target markets > Local, regional and central public
administration entities; Entities that manage municipal and
multi-municipal wastewater treatment systems
Pilot facilities > Low energy-cost system for wastewater treatment
Main clients > University of Minho (Portugal); Regional Secretariat
for Environmental and Sea (Azores, Portugal)
Technological relationships > University of Minho (Braga,
Portugal); TecMinho (Guimarães, Portugal); INOVA (Ponta Delgada,
Portugal)
[2]
Area of Biotech Activities
Health, Medical, Diagnostics > Environmental Biotechnology
> Technology Transfer, IPRs
[3]
Type of activity > Products and/or technologies from own R&D
> Services
Start up (year) > 2001
Structure of the capital > Private limited company
Percentage owned by founders > 70% STAB SGPS, 15% PME
CAPITAL, 15% CAIXA CAPITAL
Total funds raised > 750.000 EUR
Foreign revenue (%turnover 2005): 20%
Total number of employees: 14
PhD: 4 > Master of Science: 1 > Graduate: 9
Percentage of employees involved in R&D Activities: 40%
R&D Expenses (% turnover 2005) > 100%
Number of national patents:
Submitted: 05 > Awarded: 05
Number of International patents:
Submitted: 03 > Awarded: 03
[5]
Company Profile
“STAB VIDA provides genetic services: DNA sequencing, oligo
synthesis, DNA arrays, genotyping, and small genome
sequencing, as well as Legionella and Dekkera testing. STAB VIDA
has established itself as a prestigious name among researchers in
Portugal. DNA sequencing services, can be acquired through an
e-commerce platform accounts. The company operates from an
established customer base in the life sciences community,
governmental institutions, biotech companies, and hospitals.
Uniquely positioned as the only gene technology company in
Portugal, with 8 motivated, full-time employees (half with a PhD
degree) and 8-10 interns, the company is led by its CEO, Orfeu
Flores. R&D projects, such as the development of RNA stabilisers,
serve as the basis for complementary and new revenue streams.
STAB VIDA aims to be “The home for gene technology” in Iberia
and earn a reputation in Europe for high quality genetic research
and services upon which it can expand to additional profitable
markets.”
[4]
Products > Oligos, Peptides, Antibodies, Dekkera Kits
Services > DNA Sequencing, Legionella Testing, DNA Testing
Core technologies > Yeast identification/Genomics
Target markets > Clinical, Acadamic, Pharma
Facilities > IBET (Oeiras), Biocant (Cantanhede)
Main clients > All portuguese universaties, Ecogen (Spain), Hardy
Wines (Australia)
Technological relationships > Bitop (Germany)
[5]
46
Portuguese Biotechnology
DIRECTORY
47
Portuguese Biotechnology.
Life above all.
[1]
[1]
TECHNOPHAGE
THERAPROTEINS
Investigação e Desenvolvimento em Biotecnologia, SA
Theraproteins, Lda
> ADDRESS: Av. Prof. Egas Moniz, Edifício Egas Moniz, Piso 2 - A8 > ZIP CODE: 1649-028 > CITY: LISBOA
> ADDRESS: Lab 4.14, Edif IBET/ITQB, Av Republica > ZIP CODE: 2780-157 > CITY: OEIRAS
> PHONE: +351 217 999 472 > FAX: +351 217 999 459 > EMAIL: [email protected] > WEB SITE: [email protected]
> PHONE: +351 214 469 468 > FAX: +351 214 469 459 > EMAIL: [email protected] > WEB SITE: www.thera-proteins.com
> PERSON TO BE CONTACTED:
> PERSON TO BE CONTACTED: Helder Cruz
Miguel Garcia
[2]
Area of Biotech Activities
Classical Fermentation, Bioprocess Technology > Environmental
Biotechnology > Gene-based Bioindustries > Food Biotechnology,
Nutrition Science > Health, Medical, Diagnostics
The company relies on strategic partners’ capabilities to promote
clinical trials, marketing, large-scale manufacturing and
commercialization or out-licensing.
Current work is focused on the development of new products
adapted and directed to food industry and nosocomial infection.”
TheraProteins is developing routine release tests compatible with
Area of Biotech Activities
cGMP regulations for recombinant therapeutics. The company is
Health, Medical, Diagnostics
producing and marketing reference standards for recombinant
therapeutic glycoprotein analysis both for the pharmaceutical
[3]
industry and for research laboratories.”
Activity > Analysis of complex biotechnology therapeutic products
[3]
Activity > TechnoPhage, SA is a Portuguese biopharmaceutical
company, dedicated to the R&D of novel products based on the
unique properties of bacteriophages.
Type of activity > Products and/or technologies from own R&D
> Contract research > Services
Start up (year) > 2005
Structure of the capital > Private limited company
Percentage owned by founders > 100%
Total number of employees:
PhD: 2 > Master of Science: 2 > Graduate: 1
Percentage of employees involved in R&D Activities: 100%
Type of activity > Products and/or technologies from own R&D
> Services
Start up (year) > 2005
Foreign revenue (%turnover 2005): 100%
Total number of employees: 4
PhD: 2 > Graduate: 2
[4]
Products > Reference standard oligosaccharides for GMP analysis
of recombinant therapeutics
Services > Development of methods according to GMP regulations
for analysis of recombinant therapeutics
[4]
Products > Proprietary formulas for the treatment, diagnosis and
prevention of bacterial infections
Target markets > Pharmaceutical/Biotech Industry
Facilities > Headquarter and labs - IMM (Institute of Molecular
Medicine)
Core technologies > Recombinant product characterization;
development of release test protocols under GMP regulations
Target markets > Biopharmaceutical and biotechnological sectors
Facilities > One research laboratory
Main clients > Biopharmaceutical and biotechnological companies
Technological relationships > GlycoThera GmbH
[5]
Company Profile
“Founded in early 2005, TechnoPhage, SA has several players from
the HealthCare and Pharmaceutical industries, as shareholders.
Headquarter and main labs are located at the Institute of
Molecular Medicine, Lisbon, under a collaboration protocol signed
by these two entities. The research activities are being performed
mainly in these laboratories, and the development activities are
being done at the laboratories of some strategic partners from the
Pharmaceutical Industry.
48
[2]
[5]
Company Profile
“Theraproteins was founded on March 2005 and has established
its expertise in the area of recombinant protein characterisation
in partnership with the German biotech company GlycoThera.
Theraproteins is subcontractor of GlycoThera in R&D as well as
product supply.
Portuguese Biotechnology
DIRECTORY
49
Portuguese Biotechnology.
[1]
Life above all.
[1]
VSBV
WEDO TECH
Soluções de Biotecnologia para a Vitivinicultura, Unipessoal, Lda
Companhia de Ideias e Tecnologias Lda.
> ADDRESS: Av. da Liberdade,168- 4º Esq. > ZIP CODE: 4715-037 > CITY: BRAGA
> ADDRESS: Rua de S. Nicolau nº10 3º Traseiras > ZIP CODE: 4050-561 > CITY: PORTO
> PHONE: +351 96 686 94 27 > EMAIL: [email protected] or [email protected] > WEB SITE: www.vinalia.com.pt
> PHONE: +351 91 953 22 99 / +351 93 837 60 94 > EMAIL: [email protected] / [email protected]
> PERSON TO BE CONTACTED: Isabel Araújo
> WEB SITE: www.wedotech.eu > PERSON TO BE CONTACTED: Ruben Jorge / Isabel Braga da Cruz
[2]
Area of Biotech Activities
Food Biotechnology, Nutrition Science > Agricultural
Biotechnology > Technology Transfer, IPRs
[2]
Area of Biotech Activities
Food Biotechnology, Nutrition Science > Environmental
Biotechnology > Classical Fermentation, Bioprocess Technology
[3]
Type of activity > Contract research > Services
Start up (year) > 2006
Structure of the capital > Private limited company
Percentage owned by founders > 100%
Total number of employees: 2
Master of Science: 1 > Graduate: 1
Percentage of employees involved in R&D Activities: 50%
[3]
Type of activity > Products and/or technologies from own R&D
> Contract research > Services
Start up (year) > 2006
Structure of the capital > Private limited company
Percentage owned by founders > 100%
Total number of employees: 2
PhD: 1 > Graduate: 1
Percentage of employees involved in R&D Activities: 100%
[4]
Services > Investigation, formation and technical consulting
Target markets > Wine Industry
Technological relationships > University of Minho - Portugal
[4]
Products > Vapor Phase Bioreactors for air pollution control
Services > Maintenance of Vapour Phase Bioreactors
Core technologies > Biological treatment of VOC for air pollution
control, bioreactor design and specific microbial cultures
Target markets > Industrial segments with emissions that are
biodegradable.
Facilities > R&D partnership with the University.
Pilot facilities > R&D partnership with the University
[5]
Company Profile
“VSBV- Soluções de Biotecnologia para a Vitivinicultura,
Unipessoal, Lda (Vinalia) is na academic Spin-off of the University
of Minho. Is a recent company (2006) that works in the portuguese
wine, that aims to offer solutions from biotechnology for the
viticulture and winemaking. The entrepise acts in three slopes:
specialized techical assistence, formation and investigation. The
connection of the Vinalia to the University of Minho through his
statute of spin-off represents:
Investigation projects personalized and directed to a client,
support of scientific mentors (teachers and investigators of the
University of Minho, and Scientific and technological know-how.
Quality, innovation, investigation and development are the great
vectors of acting of this company.”
50
[5]
Company Profile
“A recently technology based start-up aiming at commercialising
an innovative Vapour Phase Bioreactor for air pollution control.
The marketing strategy involves the sale of the unit and the
maintenance service. Presently, 3 propotype scale reactors are
in-situ implemented.”
Portuguese Biotechnology
DIRECTORY
51
Portuguese Biotechnology.
Life above all.
[R&D INSTITUTES AND
INCUBATION CENTERS]
52
Portuguese Biotechnology
DIRECTORY
53
Portuguese Biotechnology.
[1]
Life above all.
[1]
3B’S
AIBILI
Research Group in Biomaterials, Biodegradables and Biomimetics
Association for Innovation and Biomedical Research on Light and Image
> ADDRESS: Department of Polymer Engineering, Campus of Gualtar, University of Minho > ZIP CODE: 4710-057 > CITY: Braga
> ADDRESS: Azinhaga de Santa Comba, Celas > ZIP CODE: 3000-548 > CITY: COIMBRA
> PHONE: +351 253 604 782 > FAX: +351 253 604 498 > EMAIL: [email protected] > WEB SITE: www.3bs.uminho.pt
> PHONE: +351 239 480100 > FAX: +351 239 480117 > EMAIL: [email protected] > WEB SITE: www.aibili.pt
> PERSON TO BE CONTACTED: Rui L. Reis
> PERSON TO BE CONTACTED: Cecília Martinho
[2]
Main research areas > Tissue engineering (TE) of bone, cartilage
and osteochondral defects; Production of porous biomaterials,
including rapid prototyping approaches; Systems for the
controlled release of bioactive agents, membranes for wound
dressing, hydrogels and novel degradable bone cements;
Development and modification of natural origin materials and TE
scaffolds, including patterning (nano and micro); Behaviour in
simulated physiological solutions and degradation mechanisms;
Processing and characterization of biodegradable systems and
development of bioactive and biomimetic coatings; Biomaterialsprotein interactions; Nanobiotechnology applied to regenerative
medicine; Smart-responsive materials for tissue engineering and
sustained release; Biocompatibility and immunological responses
to biomaterials; Adult Stem cells: Isolation, culturing and
differentiation; Co-culture systems for tissue engineering
applications; In-vivo tests for biocompatibility and TE constructs
functionality assessment
Created in the year > 1999
Number of Biotechnology R&D projects ongoing: 22
Number of R&D projects involving companies: 5
Total number of employees: 4 University Staff + 74 full time
researchers with research grants
Other collaborators: Several national and international
collaborators
PhD: 24 > Master of Science: 12 > Graduate: 42
Percentage of employees involved in R&D Activities: 100%
Number registered patents: 2
Annual Budget > 2 Million EUR
Percentage of the funding coming from external sources > 100%
[3]
Main Applications of Research Results > The current developments
employs the preparation of materials with distinct properties, including
54
ceramics and polymers, to be used on specific applications.
Internationally, the combination of materials technology and
biotechnology is seen as the sector in which most major breakthroughs can be expected for medical devices in the coming future.
Main International Collaboration/Connections > A large number
of Universities, R&D Institutes and companies in Europe, North
America and Asia
Main services offered to companies > The involvement of the 3B’s
Research Group with companies is mainly related to the development of research activities. In fact, the 3B’s Research Group has a
strong history of cooperation with the biomedical industry, being
well known internationally in the field of tissue engineering for its
unique interdisciplinary research approach.
Facilities > Laboratory for Surface Modification and Biomaterials
Development, of Cell Biology, of Thermal Analysis, of Materials
Processing, for Mechanical/Reological Characterization and
Scanning Electron and Atomic Force Microscopy.
[4]
Description of the R&D Institute
“The 3B’s Research Group (Biomaterials, Biodegradables and
Biomimetics) was evaluated as Excellent in the last three-year
assessment of research institutions promoted by FCT. It aims at
developing new materials to be used on a range of biomedical and
environmental applications. Its research is focused on the
development of new polymeric and composite BIOMATERIALS
from natural origin and mainly from renewable resources.Several
BIODEGRADABLE systems are being studied for applications
related with bone replacement/fixation/cements, tissue engineering scaffolding and tissue regeneration, systems for controlled
release of drugs or bioactive agents, and environmental degradable plastics. The group activities apply a research approach that
always try to learn from nature to understand its function and
mimic them, by design innovative BIOMIMETIC processing routes
and materials.”
Portuguese Biotechnology
[2]
Main research areas > Clinical Trials in Ophthalmology: diabetic
retinopathy, age-related macular degeneration, glaucoma, cataract
surgery and ocular inflammation; Bioavailability, bioequivalence
and pharmacokinetic studies; Control of raw material and
pharmaceutical formulations during the manufacturing process or
in the finished product; Development, optimisation, and validation
of analytical methods; Development of new diagnostic techniques,
with special emphasis on the area of ophthalmology; Multimodal
Macular Mapping; Processing of medical images
Created in the year > 1989
Number of R&D projects involving companies: 24
Total number of employees: 28
Other collaborators: 23
PhD: 8 > Master of Science: 10 > Graduate: 20
Percentage of employees involved in R&D Activities: 85%
Number registered patents > 1
Annual Budget > 1,2 Million EUR
Percentage of the funding coming from external sources > 95%
[3]
Main Applications of Research Results > patent for an ocular
fluorometer for clinical use; measurement of blood-retinal barrier
permeability (BRB) in human eyes (in vivo); establishment of a
correlation between various parameters of the retina providing a
global vision; techniques to process and analyse medical images
to the various types of eye fundus imaging facilitating registration
and follow-up in the daily medical practice
Main International Collaboration/Connections > Pfizer Global,
Inc.; Critical Software, S.A.; EVI – European Vision Institute; EVI.
CT.SE - European Vision Institute. Clinical Trials. Sites of Excellence;
EVIGeM – European Virtual Institute of Geometry Measurement
Main services offered to companies > Clinical Trials (Phase I, II, III
and IV); Bioavailability and Pharmacokinetic Studies; Control of
raw material and pharmaceutical formulations during the
DIRECTORY
manufacturing process or in the finished product; Development of
New Technologies for Medicine
Facilities > Building: 1.421 sq. metre; Ophthalmological
Equipment: Fluorotron Master; Laser Flare Meter; High-resolution
Ultrasound systems; Autorefractometers; Heidelberg Retinal
Tomograph (HRT II); Heidelberg Retinal Flowmeter (HRF);
Fluorotron Master; Optical Coherence Tomograph (OCT); Retinal
Thickness Analyzer (RTA); Humphrey Visual Field Analyzers (HFA II);
Topcon Imagenet System (TIS); Heilderberg Retinal; Angiograph
(HRA); Zeiss Funfus Camera; Kowa Angiograph; Laboratory
Equipment: Ultracentrifuge and Microcentrifuges;
Spectrofluorimeters; Spectrophotometers; Gas chromatography;
HPLC with fluorescence, ultra-violet and electrochemical detection;
LC/MS - Liquid Chromatography / Mass Spectometry; Liquid
scintilometry, RIA, EMIT and other methods; Sample evaporation
system under vacuum or stream of air or nitrogen; Computerized
methods of storage and handling of data.
[4]
Description of the R&D Institute
“AIBILI - Association for Innovation and Biomedical Research on
Light and Image is a private non-profit organisation, founded in
1989, established to support technology transfer to industry. AIBILI
is a Research Technology Organisation (RTO) in the Health Market
dedicated to help the development of new products for
pharmaceutical and biotechnology companies, with special
expertise in Ophthalmology. AIBILI is certified by NP EN ISO
9001:2000 since 2004, the Clinical Trials are performed in
accordance with Good Clinical Practice ICH-Guidelines and the
Bioavailability and Pharmacokinetic Studies developed in
compliance with the OCDE Principles of Good Laboratory Practice.
AIBILI has the following Units: Centre for Clinical Trials (CEC); Centre
for Bioavailability Studies (CEB); Centre of New Technologies for
Medicine (CNTM); Administrative Services (SA); Quality
Management Unit (UGQ); Technology Transfer Unit (UTT).”
55
Portuguese Biotechnology.
[1]
Life above all.
[1]
BIOCANT
Centro de Biotecnologia e Química Fina-INTERFACE A4
Associação de Transferência de Tecnologia
> ADDRESS: Rua Dr. António Bernardino de Almeida > ZIP CODE: 4200-072 > CITY: PORTO
> ADDRESS: Biocant Park - Parque Tecnológico de Cantanhede, Núcleo 04, Lote 3 > ZIP CODE: 3060-197 > CITY: CANTANHEDE
> PHONE: +351 225 580 001 > FAX: +351 225 090 351 > EMAIL: [email protected] > WEB SITE: www.esb.ucp.pt
> PHONE: +351 231 419 040 > FAX: +351 231 419 049 > EMAIL: [email protected] > WEB SITE: www.biocant.pt
> PERSON TO BE CONTACTED: Rui Morais
> PERSON TO BE CONTACTED: Carlos Faro
[2]
Main research areas > Biocant develops DNA and protein chips for
molecular diagnostics, produces recombinant protein for research
and diagnostic tests, and has a specific program on the discovery
of novel molecules with biotechnology potential, either as a result
of genome sequencing projects or through systematic screening
of samples from natural sources.
Created in the year > 2005
Number of Biotechnology R&D projects ongoing: 7
Number of R&D projects involving companies: 4
Total number of employees: 20
Other collaborators: 5
PhD: 11 > Master of Science: 3 > Graduate: 5
Percentage of employees involved in R&D Activities: 70%
Annual Budget > 1 Million EUR
Percentage of the funding coming from external sources > 50%
BIOCANT is the R&D centre of BIOCANT PARK, the first Portuguese
technology park dedicated to Biotechnology. The Centre assists
the companies of the park in their research and development
activities.”
[3]
Main Applications of Research Results > New products and
services for molecular diagnostics and therapy
Main services offered to companies > Services based on
bioinformatic, genomic, proteomic, molecular biology, cell biology
and microbiology platforms
Facilities > Biocant is organised into six R&D units: Genomics, Cell
Biology, Microbiology, Molecular Biotechnology, Bioinformatics and
Advanced services. The later includes a whole genome sequencing
unit and a proteomic facility.
includes 12 offices for faculty and post-graduate students, and
laboratories (Analytical Chemistry, Enzymatic Technology, Food
Bioprocess Technology, Non-Food Bioprocess Technology,
Microbiology I, Microbiology II, Plant Biotechnology I and Plant
Biotechnology II).
[4]
Description of the R&D Institute
“CBQF was created in 1990, involving a group of researchers from
Escola Superior de Biotecnologia (ESB) and from Faculdade de
Engenharia da Universidade do Porto. Its mission is to accomodate
R&D activities in various areas of Biotecnhology (especially focused
on the Food sector), tentatively integrated at the postdoctoral,
doctoral and master levels, via funding by external agencies in
via competitive calls, and establishing active links with industrial
companies. CBQF currently offers know-how, as well as analytical
and processing infrastructures, to the Government and the private
sector — via a contract with the Portuguese State, in two main
interdisciplinary and trans-laboratorial thematic lines: Risk
Evaluation, in the context of Food/Environmental Safety; and
Perception and Education of the Citizen, in Food/Environmental
Safety.”
[3]
Main Applications of Research Results > Dairy products, wine,
fruits and vegetables, biological treatment technologies and food
safety
Main International Collaboration/Connections
> Erasmus/Socrates, Leonardo, Fotan,Tempus, Iseki and
Erasmus-Mundus
Main services offered to companies > Scientific research and
technological training (including advanced degrees). Through AESBUC
Microbiology II, Plant Biotechnology I and Plant Biotechnology II).
Facilities > The CBQF/ESB uses a total area of 2.382 m2 — which
[4]
Description of the R&D Institute
“BIOCANT is an applied research and development center that
provides innovative services of Biotechnology relevant to Life Sciences
and promotes the development of R&D in consortium with national
and international companies to the creation of new products and
services. The Centre drives technology transfer between fundamental
research centres of known competence and biotech companies.
56
[2]
Main research areas > The R&D activities which include the
collaboration with various companies and research institutes,
national and internationaly — namely through relations
established with members of AESBUC (Associação para a Escola
Superior de Biotecnologia da Universidade Católica), area
currently arranged in four main areas: Food Science and
Technology, Environment, Enzyme and Microorganisms, and
Nutrition and Health. There is an extensive portfolio of projects
handled by CBQF — either as coordinator or collaborator, that
rceived external funding by several programs (Portuguese
agencies: Agência de Inovação, AGRO, Ciência Viva, Direcção
Geral do Ambiente, Fundação Calouste Gulbenkian, Fundação das
Universidades Portuguesas, PAMAF, POCTI, PRAXIS XXI and POCI;
European Union: BRITE, Competitive & Sustainable Growth Key
Action, CRAFT, FAIR, Human Research Potential, ICCTI, Quality of
Life Key Action, SOCRATES and ERASMUS-MUNDUS).
Number of Biotechnology R&D projects ongoing: 37
Number of R&D projects involving companies: 8
Total number of employees: 125
Other collaborators: 2
PhD: 36 > Master of Science: 7 > Graduate: 20
Number registered patents > 1
Annual Budget > 1,5 Million EUR
Portuguese Biotechnology
DIRECTORY
57
Portuguese Biotechnology.
[1]
Life above all.
[1]
CEB
CEBQ
Centre of Biological Engineering
Center for Biological and Chemical Engineering
> ADDRESS: Campus of Gualtar, University of Minho > ZIP CODE: 4710-057 > CITY: Braga, Portugal
> ADDRESS: Avenida Rovisco Pais > ZIP CODE: 1049-001 > CITY: LISBOA
> PHONE: +351 253 604 400 > FAX: +351 253 678 986 > EMAIL: [email protected] > WEB SITE: www.ceb.uminho.pt
> PHONE: +351 218 419 065 > EMAIL: [email protected] > WEB SITE: www.dequim.ist.utl.pt/cebq
> PERSON TO BE CONTACTED: Manuel Mota
> PERSON TO BE CONTACTED: J. Maggiolly Novais
[2]
Main research areas > Bioreactors and Applied Phisiology; Biofilm
Science and Engineering; Enzimatic Engineering and
Bio-Separations; Food and Chemical Technology
Created in the year > 1992
Number of Biotechnology R&D projects ongoing: 43
Number of R&D projects involving companies: 5
Total number of employees: 22
Other collaborators: 214
PhD: 54 > Master of Science: 80 > Graduate: 20
Percentage of employees involved in R&D Activities: 100%
Number registered patents > 3
Percentage of the funding coming from external sources > 75%
products or processes in the Food, Chemical, Pharmaceutical and
Environmental Industries.
Subjects where CEB-UM is recognised internationally as doing
top-level research include: Biofilms science and engineering,
Multiphase Bioreactors, Bioprocess systems analysis, Cellular and
Molecular Ecology, Carbohydrate engineering, Porous systems,
Food Safety, Anaerobic waste(water) treatment.”
[3]
Main Applications of Research Results > Process and product
design, prototype, lab-scale reactors, models, software
Main International Collaboration/Connections > MIT (USA), Lund
Univ (Sweden), DTU-Lingby (Danmark), Catolic Univ of Leuven
(Belgium), UA Barcelona (Spain), U Santiago Compostela (Spain),
LSGS Nancy (France), INSA Toulouse (France)
Main services offered to companies > Applied research in
consortia
Facilities > Image & Microscopy Laboratory, Environmental
Biotechnology Laboratory, Micology and Molecular Biology
Laboratory, Cromatography Lab., Fermentations Lab., Applied
Microbiology Lab., Chemical Engineering Lab., Biofilms Laboratory,
Enzimatical Technology and Bio-separations Lab., Food Science
and Technology Lab. and Pilot Instalations
[3]
Main Applications of Research Results > Pharmaceutical Industry,
Food and Feed Industries, Bio-medical Applications, Environmental
Protection
Main International Collaboration/Connections > A large number
of institutions in Europe and United States
Main services offered to companies > Product Development;
Environmental Protection
Facilities > Research laboratories in the fields of microbiology,
genetic engineering, stem cells, bioengineering, environmental
engineering
[4]
Description of the R&D Institute
“ CEBQ is an University Research Center which is situated at
Instituto Superior Técnico and is a part of the Associate Laboratory
IBB- Institute for Biotechnology and Bioengineering. The research
is performed both at basic and applied level in the main research
areas of the Center. Research is usually done under contract with
financing european and portuguese agencies or with industry.”
[4]
Description of the R&D Institute
“CEB is a research Centre at the University of Minho that combines
fundamental science - Chemistry, Biochemistry, Microbiology,
Molecular Biology – with Engineering Sciences – viz. Transport
Phenomena, Reaction Engineering – to obtain value-added
58
[2]
Main research areas > Microbial Physiology and Genetics, Bioengineering, Environmental Biotechnology, Chemical and Catalytic
Processes
Created in the year > 1993
Number of Biotechnology R&D projects ongoing: 40
Number of R&D projects involving companies: 8
Total number of employees: 140
PhD: 70 > Master of Science: 14 > Graduate: 56
Percentage of employees involved in R&D Activities: 100%
Number registered patents > 12
Annual Budget > 950.000 EUR
Percentage of the funding coming from external sources > 100%
Portuguese Biotechnology
DIRECTORY
59
Portuguese Biotechnology.
[1]
Life above all.
[1]
CIDEB
CMDT
Centro de incubação e Desenvolvimento de Empresas de Biotecnologia
Centro de Malária e Outras Doenças Tropicais
> ADDRESS: Rua Dr. António Bernardino de Almeida > ZIP CODE: 4200-072 > CITY: PORTO
> ADDRESS: Rua da Junqueira 96 > ZIP CODE: 1349-008 > CITY: LISBOA
> PHONE: +351 225 580 015 > FAX: +351 225 580 111 > EMAIL: [email protected] > WEB SITE: http://www.esb.ucp.pt/cebi
> PHONE: 351 213 652 658 > FAX: 351 213 652 626 > EMAIL: [email protected] > WEB SITE: www.ihmt.unl.pt/cmdt
> PERSON TO BE CONTACTED: Vítor Verdelho Vieira
> PERSON TO BE CONTACTED: Luis Távora Tavira
[2]
Main research areas > CiDEB is involved in european and national
projects to promote entrepeneurship support in incubators. For
example AFI-MAC project
Created in the year > 2004
Number of Biotechnology R&D projects ongoing: 2
Number of companies: 11 + 7 (in evaluation)
Total number of employees: 5
Other collaborators: 2
PhD: 2 > Graduate: 3
[2]
Main research areas > This Associate Laboratory has been working
in a number of RD areas including Malaria, Leishmaniasis, Human
African Trypanosomiasis, HIV/AIDS Health Systems, Sexually
Transmitted Diseases.
Created in the year > 1992
Number of Biotechnology R&D projects ongoing: 50
Number of R&D projects involving companies: 50
Total number of employees: 37
Other collaborators: 36
PhD: 30 > Master of Science: 9 > Graduate: 30
Percentage of employees involved in R&D Activities: 100%
Annual Budget > 352.050 EUR (Year:2007)
Percentage of the funding coming from external sources > 100%
[3]
Main services offered to companies > Incubation and pre-incubation services including Mentoring, Tutoring and Specialised
woorkshops
Facilities > in construction
[3]
Main International Collaboration/Connections > Faculdade de
Medicina de Maputo, Universidade de Maputo, Moçambique;
Centro Nacional de Endemias, São Tomé e Príncipe; Instituto
Evandro Chagas, Belém, Brasil; National Instituto of Healh,
Bangkok, Tailandia; Faculdade de Veterinária da Universidade
Eduardo Mondlane, Maputo, Moçambique; Centro Nacional de
Medecina Tropical, Insitut de Salud Carlos III , Espanha; Nacional de
Saúde de Luanda, Angola; Centro de Pesquisa René Rachou, Belo
Horizonte, Brasil; Danish Biharziosis Laboratory, Denmark;
Universidade de Edimburgo, Reino Unido; Universidad de
Antioquia, Medellín, Colombia
Main services offered to companies > The research that is being
carried out includes:
• Diagnostics, clinic and therapeutics in human and veterinary
health,
• Molecular epidemiology, population genetics and tropical
disease control
• Experimental models
• Susceptibility to drugs and insecticides
• Proteomic and functional genomics and
[4]
Description of the R&D Institute
“CiDEB is a technology incubator. It intends to promote the
development of integrated activities of entrepreneurship on
biotechnology-based enterprises, especially in terms of companies’
incubation and incentives to create startups (including
development of activities and related services), taking advantage
of cooperation between university and enterprise environment.
This incubator will provide different spaces to support the
incubation activity, such as: space for incubation, offices
(administrative, management), meeting room, e-learning room,
bioweb, area to make prototypes, exhibition space.”
60
Portuguese Biotechnology
DIRECTORY
• International health, health systems and biostatistics.
Facilities > The Centre is hosted at the Instituto de Higiene e
Medicina Tropical, the Portuguese centenary school of tropical
medicine, in Lisbon, with laboratories equipped for molecular
biology analyses, insectaries and animal house facilities.
[4]
Description of the R&D Institute
“The Centre of Malaria and Other Tropical Diseases is an R&D Unit
was established in 1992 at the Institute of Hygiene and Tropical
Medicine in Lisbon, Portugal. The Centre became, in 2004, an
Associate Laboratory of FCT, MCTES. Networking on national and
international levels has been a major frame of work of the Centre
in order to maximize resources and expertise.
The Centre develops research in in biomedical sciences focused on
malaria, leishmaniasis, TB, AIDS, Lyme disease, Leptospirosis,
International Health, Health Systems, Tick Transmitted Diseases,
Sexually Transmitted Diseases and Emerging and Neglected
Diseases with a number of PI´s and international collaborators.
The research that is being carried out includes:
• Diagnostics, clinic and therapeutics in human and veterinary
health
• Molecular epidemiology, population genetics and tropical
disease control
• Experimental models
• Susceptibility to drugs and insecticides
• Proteomic and functional genomics and
• International health, health systems and biostatistics.”
61
Portuguese Biotechnology.
[1]
Life above all.
[1]
CNC
IBET
Center for Neuroscience and Cell Biology
Instituto de Biologia Experimental e Tecnológica
> ADDRESS: Department of Zoology, University of Coimbra > ZIP CODE: 3004-517 > CITY: Coimbra
> ADDRESS: Estação Agronómica Nacional, Av. Da República, Qta. Do Marquês > ZIP CODE: 2784-505 > CITY: OEIRAS
> PHONE: +351 239 853 406 > FAX: +351 239 852 409 > EMAIL: [email protected] > WEB SITE: http://www.uc.pt/cnc/
> PHONE: +351 214 427 787/ +351 214 421 173 > FAX: +351 214 421 161 > EMAIL: [email protected] > WEB SITE: http://www.ibet.pt
> PERSON TO BE CONTACTED: Catarina Resende de Oliveira
> PERSON TO BE CONTACTED: Manuel Carrondo
[2]
Main research areas > The main research areas in CNC are
Neuroscience and Disease; Molecular Biotechnology and Health;
Cell and Molecular Toxicology; Microbiology; Biophysics and
Biomedical NMR; Cell and Development Biology.
Created in the year > 1990
Number of Biotechnology R&D projects ongoing: 57
Number of R&D projects involving companies: 5
Total number of employees: 33
Other collaborators: 7
PhD: 70 > Master of Science: 27 > Graduate: 34
Percentage of employees involved in R&D Activities: 58%
Number registered patents > 3
Annual Budget > 3,7 Million EUR
Percentage of the funding coming from external sources > 80%
University of Coimbra. CNC brings together scientists from the
Faculties of Science and Technology, Medicine and Pharmacy and
from the University Hospital. The CNC is structurally subdivided in
ten departments (Cell Biology, Biophysics, Biochemistry,
Neurochemistry, Neuropharmacology, Molecular Biotechnology,
Neurobiology, Microbiology, Vectors and Gene Therapy,
Graduate Studies and Advanced Strategic Studies), each headed
by a director, and the Laboratory of NMR. The various departments
collaborate in implementing strategic programmes linked to the
above mentioned research areas. Most of the programmes offer
research opportunities which span from fundamental biology to
basic and clinical research.”
[2]
Main research areas > Animal Cell Technology, Nutraceuticals and
Delivery, Genomics, Proteomics, GLP, Pilot Plant
Created in the year > 1989
Number of Biotechnology R&D projects ongoing: 140
Number of R&D projects involving companies: 90
Total number of employees: >50
Other collaborators: 120 PhD’s from other partner Institutions
like IGC, ITQB/UNL, IST/UTL, etc
Graduate: 38
Percentage of employees involved in R&D Activities: 90%
Number registered patents > 21
Annual Budget > 3 Million EUR
Percentage of the funding coming from external sources > 61%
[3]
Main Applications of Research Results > Pharmaceutical, Forestry,
Agro-industry and Environmental Industries
Main International Collaboration/Connections > Fraunhöffer
Institut, Stuttgart, Germany, Merck & Co., Merk KGAa, Schering,
CIRAD , Boehringer, Genethon
Main services offered to companies > Production of proteins,
DNA, viruses, viral particles and cells under novel bioprocessing
and downstream processes; Development and validation of
analytical methods and conduction of several studies; Detection
and quantifications of genetically modified organisms (GMO) in
food, feed and ingredients; Development of alternative green
technologies for the isolation of natural of bioactive compounds
with high added-value and application in food, cosmeceutical and
pharmaceutical industries.
[3]
Main Applications of Research Results > Development of novel
diagnostic and therapeutic strategies. Special attention is given to
translational research in particular the one underlying the “from
bench to bedside” concept
Main International Collaboration/Connections > CNC
collaborates with most of the well-known universities worldwide,
either under the framework of the international PhD Programme
on Experimental Biology and Biomedicine or through the
participation of its research groups on international projects
Main services offered to companies > R&D, microbial, molecular
and biochemical analyses
Facilities > CNC laboratories offer state-of-the -art equipment and
have access to several support facilities such as animal house, cell
culture rooms and a Life Science library
[4]
Description of the R&D Institute
“IBET is the largest not for profit Biotechnology Research
Organization in Portugal, acting as an interface to the
industries and as a support to the autonomous knowledge.
It brings together, as partners and collaborators, private
companies and public institutions, creation leading to
competencies for product and process development, of which the
most relevant is, Instituto de Tecnologia Química e Biológica (ITQB).
The private equity (58% of total) ensures that companies run IBET
under private culture and rules for the benefit of our customers.
The scientific activities of both Institutes are to provide advanced
training in an interdisciplinary environment through high quality
research work in Chemistry, Biology and associated areas,
Health/ Pharmaceuticals, Agroindustry, Forestry, Agrochemistry
and Environment.
The Pilot Plant of IBET, with 2000m2 of area, was started in 1994.
In this unit companies have access to fermentors and down-stream
processing equipment, certified for Good Manufacturing Practices.
GLP analytical microbiological / molecular biology and field trial
certification started in 1991.”
[4]
Description of the R&D Institute
“The Center for Neuroscience and Cell Biology ( CNC ) is a
non-profit biomedical research center of public utility at the
62
Portuguese Biotechnology
DIRECTORY
63
Portuguese Biotechnology.
[1]
Life above all.
[1]
ICAT
IGC
Instituto de Ciência Aplicada e Tecnologia da Faculdade de Ciências da Universidade de Lisboa
Instituto Gulbenkian de Ciência
> ADDRESS: Edf. ICAT, Campus da FCUL, Campo Grande > ZIP CODE: 1749-016 Lisboa > CITY: LISBOA
> ADDRESS: Rua da Quinta Grande, 6 - Apartado 14 > ZIP CODE: 2781-901 > CITY: OEIRAS
> PHONE: +351 217 500 006 > FAX: +351 217 500 172 > EMAIL: [email protected] > WEB SITE: www.icat.fc.ul.pt
> PHONE: +351 214 407 900 > FAX: +351 214 407 970 > EMAIL: [email protected] > WEB SITE: www.igc.gulbenkian.pt
> PERSON TO BE CONTACTED: Rogério Tenreiro
> PERSON TO BE CONTACTED: José Mário Leite
[2]
Main research areas > Molecular biology, Cell biology, Genomics,
transcriptomics and proteomics, Biotechnology, Physiology,
metabolomics and metanomics, Ecology, Microbiology,
Bioelectrochemistry, Environmental Impact Assessment and
Management, Environmental Monitoriong and Audit, Life Cycle
Assessment, Climatology and Metereology, Operational Research
Created in the year > 1989
Number of Biotechnology R&D projects ongoing: 12
Number of R&D projects involving companies: 20
Total number of employees: 17
Other collaborators: 79
PhD: 31 > Master of Science: 5 > Graduate: 43
Percentage of employees involved in R&D Activities: 47%
Number registered patents > 11
Annual Budget > 1,6 Million EUR
Percentage of the funding coming from external sources > 100%
[3]
Main Applications of Research Results > Products and Services
Main International Collaboration/Connections > Main services
offered to companies, Consultancy; Analytical Services; R&D under
contract, Alcatel Space- France, University of Leicester, Univeristy
of Loughborough Western Indian Ocean Science Association,
University of Dar Es Salaam; Center of Sustainable Development for
Coastal Zones - Mozambique, University of Eduardo Mondlane Mozambique, University of Cape Town, Oceanographic Research
Institute of South Africa, The Natural History Museum of London,
Overseas Development Group - UK, Hogskolan i Kalmer - Sweden,
World Maritime University of Sweden, Vrije Universiteit Brussel,
Umweltforschungszentrum Leipzig, University of Southern
Denmark, Universitá degli Studi di Firenze, Stockholms Universitet,
Kenya Marine & Fisheries Research Institute,Prospective College of
Engineering and Technology - Tanzania, National Environment
Management Council - Tanzania
64
Main services offered to companies > Consultancy; Analytical
Services; R&D under contract
Facilities > 3 Plant Biotechnology Laboratories; 1 Microscopy
Confocal Laboratory; 1 Plant Cell Biology Laboratory; 1 DNA
Sequencing Laboratory; 1 Microarrays Laboratory; 2 Ecology and
Instrumental Analysis Laboratories, 2 Microbial Biotechnology and
Molecular Biology Laboratories; 1 Microbiology Laboratory; Several
Administrative Offices
[4]
Description of the R&D Institute
“The Instituto de Ciência Aplicada e Tecnologia (ICAT) is a non-profit,
public benefit institution founded on May 18th 1989. ICAT’s main
goal is to improve scientific development activities, by encouraging
cooperation programs with other research and production
organizations, and interchange of knowledge and technology,
contributing to Portugal’s economical and social development.
Located in the Campus of the FCUL (major partner) ICAT thus counts
with direct linking to its human resources, about 500 professors
and investigators specialists in several areas of knowing
(Biotechnologies, Environment, Computer science, Meteorology,
among others), conferring to it a potential of critical mass extremely
high and diversified, capable to provide solutions for concrete
problems of the economic and enterprise activity. ICAT’s mission is
the creation, transference and exploitation of scientific knowledge,
with particular emphasis on the development of research in
partnership with industry, the protection of intellectual and
industrial property, the promotion of entrepreneurship and to
increase the interaction between the UL research units and
industry. ICAT’s main objectives are to implement inter-disciplinary
R&D in partnership with industry, to convey scientific and
technological knowledge to public and private institutions, to train
interdisciplinary, creative researchers and developers, to promote
entrepreneurship and to support start up and spin off companies
at the incubation stage of their activities.”
Portuguese Biotechnology
[2]
Main research areas > The Instituto Gulbenkian de Ciência’s
scientific interests are focused on the genetic basis of
development and evolution of complex systems, privileging
organism-centred approaches in experimental models that include
plants, yeast, flies and mice, and on the genetics of complex
human diseases. A strong theoretical sector (Estudos Avançados
de Oeiras, EAO) is one of the Institute’s specificities, the others
being the quality of the services, and a strong investment on
international exchange in the form of graduate courses, workshops
and symposia.
Created in the year > 1961
Number of Biotechnology R&D projects ongoing: 125
Number of R&D projects involving companies: 5
Total number of employees: 31
Other collaborators: 358
PhD: 107 > Master of Science: 6 > Graduate: 44
Percentage of employees involved in R&D Activities: 19%
Annual Budget > 8,3 Million EUR
Percentage of the funding coming from external sources > 41%
Montorotondo, Italy; CNRS, Orleans, France; MRC, Harwell, UK; IGC,
Oeiras, Portugal; Karolinska Institute, Huddinge, Sweden, HGF/GSF,
Munich, Germany and EBI, Hinxton, UK. The specific mission of the
IGC Unit within EMMA is the transfer to germ-free conditions of
targeted mouse lines with immunological defects. These lines are
then made available, upon request from interested scientists in
Europe. In order to facilitate the analysis of such animals, notably
avoiding costly special transportation at the risk of losing the
“germ-free” condition, the IGC decided to open its laboratories and
facilities to external scientists engaged in these studies. In 2000,
Dr. Martin Hrabe de Angelis was appointed Technical Director of
EMMA.
Main services offered to companies > The IGC offers library and
bio-computing services, animal SPF (Specific Pathogen Free)
facilities for mice and rats including a “germ-free” unit, a service
for production of genetically manipulated animals, high-speed
cell sorting, electron and confocal (multiphoton), microscopy,
automated DNA sequencing and “genoptyping”, GeneChip TM
technology, monoclonal antibody preparation, and Biosafety
Level3 laboratory (P3)
Facilities > Animal House; Labs; Library
[3]
Main Applications of Research Results > Biomedical
Main International Collaboration/Connections > Laboratoire
Européen Associé CNRS The LEA CNRS (Centre National de
Recherche Scientifique) was created at the IGC on September 21,
1999, by an agreement between several French (Institut Pasteur
and Université Pierre et Marie Curie) and Portuguese (Fundação
para a Ciência e Tecnologia, Instituto para a Cooperação Científica
e Tecnológica Internacional, and Fundação Calouste Gulbenkian)
organisations, aiming at synergising human competencies and
resources in research on the genetic and developmental aspects of
immunological tolerance. The LEA was created for a 4-years period.
European Mouse Mutant Archive (EMMA) The Unit for Genetic
Manipulation of Mice and Rats has joined the European Mouse
Mutant Achive (EMMA) in 1997, as one of its 7 members: CNR,
DIRECTORY
65
Portuguese Biotechnology.
[1]
Life above all.
[1]
IICT
IMM
Instituto de Investigação Científica Tropical
Instituto de Medicina Molecular
> ADDRESS: Rua da Junqueira, nº 86-1º > ZIP CODE: 1300-344 > CITY: LISBON
> ADDRESS: Av. Prof. Egas Moniz, Edifício Egas Monniz > ZIP CODE: 1649-028 > CITY: LISBON
> PHONE: +351 213 616 340 > FAX: +351 213 631 460 > EMAIL: [email protected] > WEB SITE: www.iict.pt
> PHONE: +351 217 999 411 > FAX: +351 217 999 412 > EMAIL: [email protected] > WEB SITE: www.imm.ul.pt
> PERSON TO BE CONTACTED: Sofia Lopes
> PERSON TO BE CONTACTED: Margarida Senna Martinez
[2]
Main research areas >
SUSTAINABLE DEVELOPMENT AND FOOD SECURITY (SUS):
Geographic analysis for environmental management and land
knowledge (land cover change dynamics, geomatic, geological,
pedological and mineralogical studies). Biodiversity and natural
resource studies (systematics of vascular plants, animal taxonomy,
phylogeny, ecology, biogeography, ethno-botany, conservation of
plant genetic resources and tropical wood identification and
characterization). Agricultural, forest and livestock health and
production. (integrated pest management of crops and stored
products, ethno-agronomy, animal health and nutrition, forest
production and sustainability)
BIOTECHNOLOGY: Integrated Protection of Plants and Stored
Products; Animal Health and Tropical Husbandry Plant Physiology,
Biochemistry, Molecular Biology, and Biotechnology Addressing
Plant Acclimation / Tolerance Strategies and Mechanisms and
its Relation to Productivity; Plant Biotechnology and Molecular
Biology, Addressing Aspects of Plant Biology and Development;
Post-Harvest Technology and Plant Biochemical Characterisation,
Addressing Food Security through Processing and Conservation
Issues.
Created in the year > 1883
Number of Biotechnology R&D projects ongoing: 7
Number of R&D projects involving companies: 3
Total number of employees: 187
Other collaborators: 23
PhD: 35 > Master of Science: 9 > Graduate: 41
Percentage of employees involved in R&D Activities: 53%
Annual Budget > 8,4 Million EUR
Percentage of the funding coming from external sources > 16%
stored product’s pests and diseases; Genetic and physiological
characterization of sheep adaptation to food restriction.
Characterization of African Swine Pest Virus (ASPV); Diagnosis and
study of bovine besnoitiosis; Preservation of plant genetic
resources (in vitro and by cryotechniques); Acclimation of plants
to abiotic stress; Characterization of Nitrogen-fixing root-nodule
symbioses
Main International Collaboration/Connections > Bloemfontein
University (South Africa), Institut de Recherche pour le
Développement (IRD, France), Stockholm University (Sweden),
Instituto Agronómico de Campinas, Universidade Estadual Norte
Fluminense and Universidade Federal de Viçosa (Brazil).
Facilities > diverse scientific equipment related with various
research fields
[4]
Description of the R&D Institute
“Founding date: The Cartography Commission established by the
Crown in 1883 was replaced by institutions dealing with
non-health research on Portuguese colonies with different names,
the last of which dates from 1983. The bylaws were changed in
2003, introducing global studies from the perspective of the
Community of Portuguese Speaking Countries (CPLP), with which
an agreement was signed in 2004.
Objectives: IICT is a State Laboratory in the Ministry of Science,
Innovation and Higher Education. Its Steering Committee includes
representatives of the Ministries of Economics, Foreign Affairs, of
business associations, foundations and international organisations.
There are research programs in biodiversity and natural resources,
environment and earth sciences, sustainable agriculture and food
safety, forests and forest products history and cartography, tropical
societies and cultures, and global development.”
[3]
Main Applications of Research Results > Biological control and
biotechniques as an alternative to chemical control of plant and
66
Portuguese Biotechnology
[2]
Main research areas > Cell and Developmental Biology;
Immunology and Infectious Diseases; Neurosciences; Oncology
Created in the year > 2002
Number of Biotechnology R&D projects ongoing: 50
Number of R&D projects involving companies: 5
Total number of employees: 21
Other collaborators: 233
PhD: 104 > Master of Science: 10 > Graduate: 120
Percentage of employees involved in R&D Activities: 100%
Number registered patents > 2
Annual Budget > 3,5 Million EUR
Percentage of the funding coming from external sources > 99%
[3]
Main Applications of Research Results > Pharmaceutical, Health
and Biotechnological processes and products. Amongst the
pathologies investigated at IMM, emphasis is given to diseases
caused by ischaemia (namely cerebral thrombosis) and neuronal
degeneration (Alzheimer’s disease and Parkinson’s disease).
Ongoing research projects are targeted at developing new cellular
and pharmacological treatments for neuronal injury and improved
methods for the induction of new vessels in situations of ischaemia.
In parallel, the role of diet and the predictive value of mutations in
genes candidate to risk/susceptibility factors for cardio and
cerebrovascular diseases are studied. IMM research teams also focus
on the development of experimental treatments against cancer and
infectious diseases (namely AIDS, herpes and hepatitis C) and
investigate the mechanisms that lead to antiviral and antibacterial
drug resistance. Collaboration with Portuguese start-up companies
such as Genomed, Tecnophage and Alfama.
Main International Collaboration/Connections > At present, IMM has
research collaborative protocols with Units at the Faculty of Pharmacy
(University of Lisbon), the Faculty of Sciences (University of Lisbon) and
Instituto Nacional de Saúde Ricardo Jorge. IMM is also actively
engaged in collaborative research projects with Instituto Gulbenkian
DIRECTORY
de Ciência, Instituto de Tecnologia Química e Biológica e Instituto
Superior Técnico. IMM Research Group Leaders are currently involved
in several International networks EU(DGXII – Research), ESF (European
Science Foundation), HHMI (Howard Hughes Medical Institute) and
HFSP (Human Frontier Science Program)
Main services offered to companies > IMM researchers have
established research contracts with the following companies
(among others): Exelixis, Inc; GEMI Fond Grant 2005; MERCK,SA ;
NOVARTIS Consumer Health, SA; Gerling,AG; Bristol Myers Squibb;
Regeneron Pharmaceuticals, USA
Facilities > Cell sorting and flow cytometry; Advanced light
microscopy; Microarray analysis; Animal house
[4]
Description of the R&D Institute
“Understanding the causes and finding treatment for most diseases,
which involve complex interactions between environmental and
genomic factors is a major challenge that faces medical research today.
IMM is a Private, Non-profit Association, whose associate members are
the University of Lisbon, the University of Lisbon School of Medicine,
the Santa Maria Hospital, the Portuguese Institute of Oncology, the
University of Lisbon Foundation, the Association for Research and
Development of the University of Lisbon Medical School, and the
Oriente Foundation. IMM has the potential to provide a unique
research environment where a new generation of world class leaders
can be nurtured. An important added value derives from the close
interactions between IMM, the medical school and the University
hospital. These three entities established a consortium to promote
translational research by providing a framework to develop pre-clinical
research, clinical research and new technologies, which is excellently
positioned to disseminate new discoveries to university education, to
the biotech and pharmaceutical industry, and to medical practitioners.”
67
Portuguese Biotechnology.
[1]
Life above all.
[1]
INEB
INETI
Instituto Nacional de Engenharia Biomédica
Department of Biotechnology
> ADDRESS: Rua do Campo Alegre, 823 > ZIP CODE: 4150-180 > CITY: PORTO
> ADDRESS: Estrada do Paço do Lumiar, 22 Edif. F r/c & Edif E > ZIP CODE: 1649-038 > CITY: LISBON
> PHONE: +351 226 074 982 > FAX: +351 226 094 567 > EMAIL: [email protected] > WEB SITE: www.ineb.up.pt
> PHONE: +351 217 163 640 > FAX: +351 217 163 636 > EMAIL: [email protected] > WEB SITE: www.ineti.pt
> PERSON TO BE CONTACTED: Ana Paula Filipe
> PERSON TO BE CONTACTED: José Carlos Roseiro
[2]
Main research areas > Biomaterials; Biomedical Signal and Image
Created in the year > 1989
Number of Biotechnology R&D projects ongoing: 20
Total number of employees: About 90 persons work at INEB, 13 of
which are “employees”
Other collaborators: 9
PhD: 31 > Master of Science: 18 > Graduate: 25
Percentage of employees involved in R&D Activities: 94%
Number registered patents > 3
Annual Budget > 1,1 Million EUR
Percentage of the funding coming from external sources > 98%
[3]
Main Applications of Research Results > Biomedical implants,
tissue regeneration, non-invasive diagnosis systems, biomedical
simulators
Main International Collaboration/Connections > INEB has
collaborations with many of the most relevant scientists and
groups in Australia, China, Europe, Japan, South America, Japan
and the US, resulting in exchanges and co-supervision of
post-graduate students and joint publications in international
journals. In terms of numbers, in the period of 2001-2005 INEB had
25 projects involving foreign institutions, collaborations with more
than 40 foreign institutions and 10 companies, 18 research
trainings abroad and 12 visiting researchers (periods > 1 week).
Main services offered to companies > SUIM is a facility of INEBInstituto de Engenharia Biomédica, providing services and
technical training to research centers and industry in the areas of
interfaces and macromolecules. SUIM facilities include advanced
physical, chemical and structural characterization techniques
particularly devoted to the study of materials surfaces, going down
to the microscopic and nanoscopic levels. The techniques available
at SUIM complement those existing at CEMUP-Centro de Materiais
da Universidade do Porto (SEM - scanning electron microscopy,
EDS - energy dispersive analysis, and XPS - X-ray photeoelectron
68
spectroscopy) and IBMC -Instituto de Biologia Molecular (e.g.
laser confocal microscopy and transmission electron microscopy)
and include several advanced techniques suitable for the study
of surfaces and interfaces of materials with cells and tissues.
SUIM is located in the same building as IBMC and next to CEMUP,
thus making access to all these complementary techniques very
convenient.
Facilities > The Biomaterials Laboratory is located at a
building shared with the Instituto de Biologia Molecular e Celular
(IBMC), whereas the Signal and Image Laboratory is located at the
Faculdade de Engenharia da Universidade do Porto (FEUP).
The existence of two sites permits INEB to have access to advanced
engineering and molecular and cell biology facilities.
[4]
Description of the R&D Institute
“INEB has four working Groups: the Biointerface Group focus on the
tissue-material interface, at cellular levels. The approach is to study and
modify the tissue-material interface based on cross-cutting
methodologies, namely tissue engineering and nanotechnologies,
and the necessity to develop devices that meet patient needs.
The Bioceramics and Glasses Group devotes the research to the
development of novel synthetic bone grafts for the treatment of
clinical situations associated with bone trauma, bone disease and
ageing. This Group is focused on Clinical evaluation of the bone grafts,
development and clinical evaluation of ceramic-based drug delivery
systems for therapeutic molecules and manufacture of custom-made
implants and prosthesis for bone-associated pathologies.The Biomedical
Imaging and Vision Computing Group addresses the Image Analysis in
Medicine and Biology program and the Vision Computing and
Biomedical Modelling. The Signal Processing Group unites researchers
in signals and systems engineering and clinical monitoring. Its activities
range from basic research on advanced classification methods to
development of technological solutions for specific clinical problems.”
Portuguese Biotechnology
[2]
Main research areas > Protein and Monoclonal Antibody
Technology > Monitoring and Ecotoxicity > Bioengineering and
Bioprocessing > Microbial Physiology and Bioprocesses > New
Forms of Bioactive Agents > Laboratory of Industrial Microbiology
> Molecular Biology Group
Total number of employees: 69
Other collaborators: 25
PhD: 22 > Master of Science: 3 > Graduate: 33
Percentage of employees involved in R&D Activities: 83
Number registered patents > 20
Annual Budget > 600.000 EUR
[3]
Main Applications of Research Results > Environmental, Industry
and Health.
Main International Collaboration/Connections > European
Main services offered to companies > Microbiology; Biomass:
Research
Facilities > Research Laboratories; Acredited Microbiology Lab;
Fermentation Pilot Plant
DIRECTORY
69
Portuguese Biotechnology.
[1]
Life above all.
[1]
INIAP
INOVAR & CRESCER
Instituto Nacional de Investigação Agrária e Pescas
Incubação e Inovação em Saúde (Farmaco-Clínica), com Intervenção em Diagnóstico e Empreendedorismo
> ADDRESS: R. Barata Salgueiro, 37, 4º > ZIP CODE: 1250-042 > CITY: LISBOA
> ADDRESS: Rua Dr. António Bernardino de Almeida > ZIP CODE: 4200-072 > CITY: PORTO
> PHONE: +351 213 131 700 > FAX: +351 213 131 783 > EMAIL: [email protected] > WEB SITE: www.iniap.min-agricultura.pt
> PHONE: +351 225 580 015 > FAX: +351 225 580 111 > EMAIL: [email protected]
> PERSON TO BE CONTACTED: José Aguiar
> PERSON TO BE CONTACTED: Vítor Verdelho Vieira
[2]
Main research areas > INIAP is divided in 2 major research
areas : agro/rural and sea/fisheries. The agro/rural structure
of INIAP is concerned with the following scientific areas:
Natural resources and environment; Plant protection; Genetic
resources and plant breeding; Viticulture and œnology; Olives and
olive oil; Horticulture, fruit-growing; Forestry and forest products;
Animal nutrition and feeding; Animal production technologies; Animal
reproduction, genetics and breeding; Preservation technologies;
Agrarian economy and sociology. The sea and fisheries structure
of INIAP is concerned with the following scientific areas: Scientific
basis for the integrated management of fisheries’ resources; Local
and coast fisheries; Environmental changes and interaction with the
productive resources and systems; environmental contamination
and alive sea resources; Improvement of the aquicultural production;
Diversification and demonstration of production of fish and bivalves;
Improvement and quality of fisheries’ products; Safety of bivalves.
Created in the year > 2002 as the merging result of INIA (f. 1975)
and INIP/IPIMAR (f. 1978)
Number of Biotechnology R&D projects ongoing: 218 (including
Biotech projects)
Number of R&D projects involving companies: 78
Total number of employees: 1021
PhD: 79 > Master of Science: 53 > Graduate: 322 > Students: 177
Percentage of employees involved in R&D Activities: 75%
Number registered patents > 45 ( plant varieties)
Annual Budget > 42 Million EUR
Percentage of the funding coming from external sources > 20%
[3]
Main Applications of Research Results > Agriculture, forest,
livestock and fisheries related activities > Food quality and safety
> Environment
Main International Collaboration/Connections > INIAP represents
Portugal in the EU Standard Committee for Agricultural Research
and collaborates with European institutions in the initiatives it has
70
been promoting for ERA-NET projects. INIAP represents FCT in the
ongoing SAFEFOODERA. At international level, INIAP is a
participant in the CIRAD-led European project ALCUE-Food. INIA
has protocols and co-operates with several entities, participates in
several internationals networks and participates in various Cost
Actions. IPIMAR has privileged collaborations with institutions
having similar activities in all the State Members within the
European Union, International organizations for fisheries and sea
and European universities. INIAP is represented in national and
international advisory boards, and in various working groups, in
National Boards, as well as in 16 Standardization technical
Committees. The INIA domain has a privileged collaboration with
several institutions within the Veterinarian and Agrarian Sciences
domain. Through the IPIMAR structure, and concerning the type of
activity it carries out, there are multiple collaborations with other
institutions from the same Ministry, other Ministries, Universities
and sector professional associations.
Facilities > Agricultural research infra-structures and Fisheries
research infra-structures (Experimental Facilities for Aquaculture;
Artificial Reefs; Laboratory Facilities)
[4]
Description of the R&D Institute
“The Institution is responsible for performing the research,
experimentation and demonstration activities necessary for the
reinforcement of agriculture, animal production and forests and
to provide expert advice to the Administration in all these areas,
as well as to perform scientific research, technological innovation
and demonstration activities in the areas of fisheries, aquaculture,
transformation industries and marine environment and to provide
scientific advice to National and European Fisheries Administration,
and contribute to the definition of fisheries and aquaculture management policies. INIAP involves 8 research institutions concerned
with: agronomy research and plant breeding (4), forestry research
(1), animal breeding (1), fisheries and aquaculture research (1), soil,
fertilizer and plant analysis (1).”
Portuguese Biotechnology
[2]
Main research areas > Inovar & Crescer is an incubator which is in
construction, its focus is on health and diagnostic products.
Created in the year > 2005
Number of companies: 4 + 2 (in evaluation)
Total number of employees: 3
Other collaborators: 3
Graduate: 3
[3]
Main services offered to companies > Incubation and
pre-incubation services incl. Mentoring, Tutoring and Specialised
woorkshops
Facilities > in construction
[4]
Description of the R&D Institute
“I&C intends to promote the entrepreneurship of
technological-based enterprises, specifically the incubation of
companies in the area of the health, with intervention at a
pharmacological- clinical level and diagnosis, taking advantage
of university, R&D institutes, entities of interface and companies,
with experience and interest in this area.”
DIRECTORY
71
Portuguese Biotechnology.
[1]
Life above all.
[1]
INSA
IPATIMUP
Instituto Nacional de Saúde Dr. Ricardo Jorge
Instituto de Patologia e Imunologia Molecular da Universidade do Porto
> ADDRESS: Av. Padre Cruz > ZIP CODE: 1649-016 > CITY: LISBOA
> ADDRESS: Rua Dr. Roberto Frias s/n > ZIP CODE: 4200-465 > CITY: PORTO
> PHONE: +351 217 519 200 > FAX: +351 217 526 400 > EMAIL: [email protected] > WEB SITE: www.insarj.pt
> PHONE: +351 225 570 700 > FAX: +351 225 570 799 > EMAIL: [email protected] > WEB SITE: www.ipatimup.pt
> PERSON TO BE CONTACTED: Susete Luís
> PERSON TO BE CONTACTED: Manuel Sobrinho Simões
[2]
Main research areas > Infectious diseases; chronic-degenerative
diseases; environment related health problems; food safety and
nutrition
Created in the year > 1899
Total number of employees: 550
PhD: 33 > Master of Science: 14 > Graduate: 237
Percentage of employees involved in R&D Activities: 12%
Annual Budget > 29 Million EUR
Percentage of the funding coming from external sources > 68%
[3]
Main Applications of Research Results > The main application of
the results stemming from the research conducted at INSA is the
support to decision making. Clinicians and other health
professionals, local authorities, health administrators and health
policy-makers all largely benefit from INSA’s R&D output. Recent
examples include novel diagnostic and prognostic tools in
oncology, in vitro diagnosis technology assessment or health
impact mitigation measures in uranium mining areas. On the other
hand, basic research results are often channelled towards
downstream projects, e.g., the development of a mathematical
model describing the impact of heat on human mortality was
instrumental in setting up a heat-wave social warning system.
Main International Collaboration/Connections > Besides inherent
cooperation in R&D activities, INSA projects itself internationally
through the participation in scientific networks.
Program EU-IBIS-Haemophilus influenzae: European Union Invasive
Bacterial Infections Surveillance Network; Program European Invasive
Bacterial Infection Surveillance (EU-IBIS) - Neisseria meningitidis;
Programa EARSS (European Antimicrobial Resistance Surveillance
System); Programa “ENTER-NET - International Surveillance Network
for Enteric Infections”
Salmonella, E.coli and Campylobacter; Network Pulse-net Europe;
ESSTI: European Surveillance of Sexually Transmitted Diseases;
EURO-TB; EUROFIR; ICREW.
72
Main services offered to companies > Servicing is, along with R&D
and health monitoring, part of its mission as a health State laboratory.
INSA provides services in clinical and environmental analyses,
external laboratory quality assessment programs, technical and
scientific consulting/support and external trainings.
Facilities > INSA currently incorporates Operative Units in the
main-office, in Lisbon, in Porto’s office and in the Águas de Moura –
Palmela study centre.
[4]
Description of the R&D Institute
“INSA is a complex set of Operational Units that cover the main
current health concerns and is officially recognised as a National
Public Health State laboratory, The National Observatory of Health
and the National Referencing Laboratory.
As a hole, INSA is expected to contribute to public health
improvement [aim] based upon the best possible evidencing
[action pattern] through the four steps of human health risk
assessment - hazard identification, exposure assessment,
dose-response assessment, and risk characterization, articulating
[strategy] for risk management (and public information) with other
national (General Directorate of Health, health authorities, health
services (in general) and other public domain services) and
international (World Health Organisation, European Union) entities
when necessary. In order to accomplish its mission and goals, INSA
currently uses as main referentials both the relevant national
legislation and the National Health Plan for 2004-2010 to orientate
its R&D activity, health monitoring and servicing in main areas of
scientific Intervention such as: infectious diseases, chronic
degenerative and genetic disorders, environment related health
issues, food safety and nutrition, health indicators, and others that
may be regarded of public interest (e.g. rare diseases and orphan
diseases).
These activities are directly related to INSA’s four strategic
functions: State Laboratory, Referencing Laboratory, National
Observatory of Health, Science Disseminator.”
Portuguese Biotechnology
[2]
Main research areas > Human pathology and genetics, with
particular emphasis on oncobiology.
Created in the year > 1989
Number of Biotechnology R&D projects ongoing: 15
Total number of employees: 23
Other collaborators: 80
PhD: 51 > Master of Science: 10 > Graduate: 41
Percentage of employees involved in R&D Activities: 90%
Annual Budget >3,5 Million EUR
Percentage of the funding coming from external sources > 75%
For the most part, the research of IPATIMUP can be defined as
translational research: bridging the gap between clinical problems
and basic science; focusing on health problems of the Portuguese
population.
The primary research target is gastric carcinoma-etiopathogenesis,
precursor lesions, advances in diagnosis and prognosis — an area
where IPATIMUP is a world leader.
Other fields of interest are: thyroid and breast cancer and precancerous conditions; prevention of gastrointestinal, liver and cervix
cancer; mechanisms of cell differentiation and death in leukaemia
and lymphomas; identification and study of genetic susceptibilities
in the Portuguese population.”
[3]
Main Applications of Research Results > Pharmaceutical and kits
for diagnosis
Main International Collaboration/Connections > CNIO - Centro
Nacional de Investigaciones Oncologicas, Espanha; Norwegian
Cancer Institut; British Columbia Cancer Agency, Canada;
Universities of Amsterdam, Copenhagen, Ghent, Kansas, Omaha,
Santiago de Compostela, Munchen, Zhengzhou
Main services offered to companies > Research; for patients,
providing of sophisticated diagnostic expertise in the different
fields covered by the Institute - Pathology, Oncobiology and
Population Genetics.
Facilities > A building of 4,000 m2 in Porto, near Hospital S. João
[4]
Description of the R&D Institute
“IPATIMUP main goals are: research in human pathology, with
particular emphasis on oncobiology; training of graduate students,
technicians, residents and specialists in pathology; diffusion of
scientific knowledge and teaching of undergraduate students;
providing sophisticated diagnostic expertise in the different fields
covered by the Institute: pathology, oncobiology and population
genetics.
DIRECTORY
73
Portuguese Biotechnology.
[1]
Life above all.
[1]
ITQB
REQUIMTE
Instituto de Tecnologia Química e Biológica
Laboratório Associado para a Química Verde Tecnologias e Processos Limpos
> ADDRESS: Av. Republica, Estação Agronómica Nacional > ZIP CODE: 2780-157 > CITY: OEIRAS
> ADDRESS: Faculdade de Ciência e Tecnologia - UNL - QUINTA DA TORRE > ZIP CODE: 2829-516 > CITY: CAPARICA
> PHONE: +351 214 469 318 > FAX: +351 214 469 314 > EMAIL: [email protected] > WEB SITE: www.itqb.unl.pt
> PHONE: +351 212 948 381 > FAX: +351 212 948 575 > EMAIL: [email protected] > WEB SITE: www.requimte.pt
> PERSON TO BE CONTACTED: Lurdes Conceição
> PERSON TO BE CONTACTED: Isabel Maria Andrade Martins Galhardas Moura
[2]
Main research areas > Synthesis and characterization of molecules
with biological activity; Improvements of plants and forestry;
Fundamental and clinical microbiology; Structural and functional
studies of proteins; Technologies associated with food, health, and
the environment
Created in the year > 1989
Number of Biotechnology R&D projects ongoing: 7 (out of 103
ongoing projects in the areas of chemistry and life sciences)
Number of R&D projects involving companies: Projects involving
companies run in collaboration with IBET
Total number of employees: 123
Other collaborators: 306 (including scholarships)
PhD: 132 > Master of Science: 11 > Graduate: 65
Percentage of employees involved in R&D Activities: 85,50%
Number registered patents > Patents resulting from ITQB research
are submitted through IBET
Annual Budget > 8,5 Million EUR
Percentage of the funding coming from external sources > 55%
each of them designed for four research workers and a supervisor.
Some facilities are located in two other buildings, one
belonging to the Agricultural Station and the other to the
neighbouring Gulbenkian Institute. The Institute is equipped
with multiple state of the art equipment, greenhouses, analytical
services, and a pilot plant.
[4]
Description of the R&D Institute
“Instituto de Tecnologia Química e Biológica (ITQB) is a research
institute of the Universidade Nova de Lisboa. Its mission is also
to provide advanced training in an interdisciplinary environment
through high quality research work in Chemistry, Biology and
associated technologies. Since 2001, ITQB together with Instituto
Gulbenkian de Ciência and Instituto de Biologia Experimental e
Tecnológica (IBET) constitutes an Associate Laboratory.”
[3]
Main Applications of Research Results > The major output of ITQB
is to generate and foster scientific knowledge from which
applications may be derived in areas such as health,
pharmaceutical, food industries and agriculture.
Main International Collaboration/Connections > ITQB’s
laboratories have extensive international collaborations with
numerous laboratories in other universities, research institutes and
companies, both in Europe and USA. ITQB also collaborates with
large European Organizations such as ESRFand EMBO.
Main services offered to companies > ITQB provides a number of
analytical services wich are also available to external investigators.
These include, Amino Acid Analysis, Small Molecule X-Ray
Crystalography, Protein Sequencing, Elemental Analysis, Mass
Spectrometry and Nuclear Magnetic Ressonance.
Facilities > The building includes 56 modular research laboratories,
74
[2]
Main research areas > Natural Products:screening And Synthesis >
Food Quality And Safety > Clean Technologies And Clean Processes
> Bioremediation > Catalysts, Solvents And Non-toxic Compounds
Created in the year > 2001
Total number of employees: 374
PhD: 208 > Graduate: 104
Percentage of employees involved in R&D Activities: 100%
Number registered patents > 7
Annual Budget > 2 Million EUR
Percentage of the funding coming from external sources > 34%
of Sustainable Products and Processes that will reduce life cycles
environmental impacts.
REQUIMTE has also as one of its main objectives the training of
post-graduate students in interdisciplinary areas related with
Sustainable Chemistry. In the year of 2005, 19 Ph.D. thesis and 17
Ms.C. have been presented.”
[3]
Main Applications of Research Results > design of sustainable
products and processes
Main International Collaboration/Connections > Green
Chemistry Network, European Networks
Main services offered to companies > consulting, development of
prototypes, analytical methodologies, spectroscopic analysis
Facilities > NMR, EPR, MS, AA Sequencer, Metal Analysis (ICP), Pilot
Plant
[4]
Description of the R&D Institute
“REQUIMTE (Rede de Química e Tecnologia) results from a
collaboration between two university based research Centers
“CQFB: Centro de Química Fina e Biotecnologia da Universidade
Nova de Lisboa“ and - CEQUP: Centro de Química da Universidade
do Porto“.
The scientific expertise and complementary knowledge available
in the basic areas of chemistry, biochemistry and chemical
engineering is focused on the principles of Green Chemistry in
order to implement the use of cleaner products and cleaner
technologies thus preventing pollution at its source.
REQUIMTE aims to develop and assist manufacturers in the design
Portuguese Biotechnology
DIRECTORY
75
Portuguese Biotechnology.
[INDEX]
[1]
TECMINHO
Introduction
KTO of UMinho
> ADDRESS: Campus of Azurém, University of Minho > ZIP CODE: 4800-057 > CITY: Guimarães, Portugal
Tec
inho
> PERSON TO BE CONTACTED: Ana Paula Amorim
[2]
Main research areas > TecMinho is the KTO (Knowledge
Tranfer Office) of University of Minho and is responsible for the IP
management and commercialisation as well as the valorisation of
its technology portfolio. UMinho has two centres of excellence in
biotechnology: 3B’s Group, and Centre of Biological Engineering. Here
follows examples of on going PCT applications: Setting Process of
Cr(VI) in a Faujasite Zeolite (FAU): This technology is intended to
remove hexavalent chromium at low concentrations (till 250 mg/
L). The removal is done through the use of a bacterial biofilm
(Arthrobacter viscosus) supported on a zeolite of faujasite. The
biofilm will reduce the Cr(VI) to Cr(III), which will then be fixed in
the zeolite by ion exchange. The preparation of the biosorvent is
done inside a reactor, where the microorganism is put in contact
with the zeolite and some nutrients that will favor the growth of
the Arthrobacter viscosus. The microorganism will grow creating a biofilm
around the surface of the zeolite. Functionalization of biomedical
materials using a Carbohydrate binding domain: This technology
consists on the identification of a novel peptide sequence which
has affinity for starch. These peptides are part of the family of
CBMs, which enable proteins to bind, reversibly or irreversibly, to
carbohydrates.Other starch binding domains have been reported,
but this technology reports a novel one, derived from a human
protein with affinity for glycogen (laforin, a phosphatase protein).
The technology, in its current state of development, enables the
recombinant production, in E. coli., of a protein of interest fused
to the identified human starch binding domain. The production of
the recombinant protein follows standard laboratory techniques
which are easy to scale up and result in the production of large
amounts of material.
Created in the year > 1990
Total number of employees: 25
Master of Science: 2 > Graduate: 20
Number registered patents > 51 (UMinho)
Annual Budget > 1,9 Million EUR
Percentage of the funding coming from external sources > 80%
76
[4]
Description of the R&D Institute
“ TecMinho is a non-profit association, funded in 1990 as an
interface of University of Minho, and is nowadays responsible for
the valorisation of the knowledge generated in this university
in particular IP management and commercialization through
the Department of Technology Transfer. The KTO is hosted and
operationalised by the Dept. of TT of TecMinho and is based in
three independent structures that are coordinated by the Director of that department: OTIC: with the mission to promote/enhance knowledge transfer, through Partnering (establishment of
strategic partnerships based on Contracts/Collaborative Research
and Licensing) and supported by a Science Marketing Action
Plan; PatentInova: with the mission to set up technology based
spin-offs, managing the Campus Companies Programme (the first
phase of their life cycle) and set up and manage ‘proof-of-concept’
funds; GAPI: with the mission to scout technologies and protect IP
through all its legal process.”
Portuguese Biotechnology
42
43
SIMBIENTE
44
8
STAB VIDA
45
9
TECHNOPHAGE
46
BEBE VIDA
10
THERAPROTEINS
47
BIOALVO
11
VSBV
48
BIOCODEX
12
WEDO TECH
49
BIOEPI
13
[R&D INSTITUTES]
BIOESTRATEGIA
14
AIBILI
53
BIOGNOSIS
15
CBQF
55
BIOPREMIER
16
CEB
56
BIOSTRUMENT
17
CIDEB
58
BIOSURFIT
18
CMDT
59
BIOTECA
19
CNC
60
BIOTECNOL
20
IBET
61
BIOTEMPO
21
ICAT
62
BIOTESTE
22
IGC
63
BIOTREND
23
IICT
64
BLUEPHARMA
24
IMM
65
CPC
25
INEB
66
CRIOESTAMINAL
26
INETI
67
CYTOTHERA
27
INIAP
68
ECBIO
28
INSA
70
29
IPATIMUP
71
FOODMETRIC
30
ITQB
72
GENE EXPRESS
31
REQUIMTE
73
GENE PREDIT
32
[INCUBATIONS CENTERS]
GENEBOX
33
3B’S
52
GENELAB
34
BIOCANT
54
GENETEST
35
CEBQ
57
GENIBET
36
INOVAR & CRESCER
69
GENOMED
37
TECMINHO
74
HALORIS
38
ATGC
[3]
Main Applications of Research Results > The research results can
be applied in the creation of a spin-off (“campus-companies”).
UMinho has 2 “campus-companies” in Biotechnology: Biotempo
and Simbiente that resulted from activities of researchers from the
Department of Biological Engineering of UMinho. Now, TecMinho
is setting up a spin-off (“campus-company”) on “Enzimatic
Bonding”: Biologically, enzymes are involved in practically all
chemical processes, able to catalyse both the synthesis and
degradation of organic materials. In other instances, the
advantages of using enzymes are that they can catalyse highly
specific reactions and that, because they occur naturally, they
entail only very few or no environmental or health risks
Main International Collaboration/Connections > Licensing,
contract / collaborative research.
Main services offered to companies > IP management,
consultancy
NECTON
PROENOL
[COMPANIES]
ALFAMA
> PHONE: +351 253 510 596 > FAX: +351 235 510 591 > EMAIL: [email protected] > WEB SITE: www.tecminho.uminho.pt
5
EUROTRIALS
IMUNOSTAR
39
INTRANSTEC
40
ITB
41
Com o apoio do INETI
ICEP Portugal
Av. 5 de Outubro, 101
1050-051 Lisboa
Telefone: +351 217 909 500 Fax: +351 217 909 586
e-mail: [email protected]
web-site: www.icep.pt
APBio - Associação Portuguesa de Bioindústrias
Taguspark - Núcleo Central, sala 43
2740-122 Oeiras
Telefone: +351 214 217 710 Fax: +351 214 216 574
e-mail: [email protected]
web-site: www.apbio.pt
Life Sciences & Biotechnology